Full text of the official published hearing record. Extracted from the source document — verify against the official record for citation.
[Senate Hearing 119-545] [From the U.S. Government Publishing Office] S. Hrg. 119-545 HALF THE COUNTRY, ZERO HEARINGS: MEETING THE MOMENT TO END THE MENOPAUSE CARE GAP IN AMERICA ======================================================================= HEARING BEFORE THE SPECIAL COMMITTEE ON AGING UNITED STATES SENATE ONE HUNDRED NINETEENTH CONGRESS SECOND SESSION __________ WASHINGTON, DC __________ SEPTEMBER 16, 2026 __________ Serial No. 119-35 Printed for the use of the Special Committee on Aging [GRAPHIC NOT AVAILABLE IN TIFF FORMAT] Available via the World Wide Web: http://www.govinfo.gov __________ U.S. GOVERNMENT PUBLISHING OFFICE 65-552 PDF WASHINGTON : 2026 ======================================================================= SPECIAL COMMITTEE ON AGING RICK SCOTT, Florida, Chairman DAVE McCORMICK, Pennsylvania KIRSTEN E. GILLIBRAND, New York JIM JUSTICE, West Virginia ELIZABETH WARREN, Massachusetts TOMMY TUBERVILLE, Alabama MARK KELLY, Arizona RON JOHNSON, Wisconsin RAPHAEL WARNOCK, Georgia ASHLEY MOODY, Florida ANDY KIM, New Jersey JON HUSTED, Ohio ANGELA ALSOBROOKS, Maryland ---------- McKinley Lewis, Majority Staff Director Claire Descamps, Minority Staff Director C O N T E N T S ---------- Page Opening Statement of Senator Kirsten E. Gillibrand, Ranking Member......................................................... 1 Opening Statement of Senator Rick Scott, Chairman................ 2 PANEL OF WITNESSES Jean Wactawski-Wende, Ph.D, Dean and SUNY Distinguished Professor, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York....................... 4 Lynne M. Coslett-Charlton, MD, FACOG, MSCP, Gynecologist, American College of Obstetricians and Gynecologists, Pittston, Pennsylvania................................................... 6 Jennifer Weiss-Wolf, JD, Executive Director, Birbaum Women's Leadership Center at NYU Law, New York, New York............... 8 Suzanne Silverman Fenske, MD, FACOG, ABOIM, MSCP, Double Board- Certified Gynecologist, Founder, TaraMD, Women's Health Ambassador, HHS Office on Women's Health, New York, New York... 10 APPENDIX Prepared Witness Statements Jean Wactawski-Wende, Ph.D, Dean and SUNY Distinguished Professor, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York....................... 28 Lynne M. Coslett-Charlton, MD, FACOG, MSCP, Gynecologist, American College of Obstetricians and Gynecologists, Pittston, Pennsylvania................................................... 33 Jennifer Weiss-Wolf, JD, Executive Director, Birbaum Women's Leadership Center at NYU Law, New York, New York............... 35 Suzanne Silverman Fenske, MD, FACOG, ABOIM, MSCP, Double Board- Certified Gynecologist, Founder, TaraMD, Women's Health Ambassador, HHS Office on Women's Health, New York, New York... 53 Questions for the Record Jean Wactawski-Wende, Ph.D, Dean and SUNY Distinguished Professor, School of Public Health and Health Professions, University at Buffalo, Buffalo, New York....................... 59 Lynne M. Coslett-Charlton, MD, FACOG, MSCP, Gynecologist, American College of Obstetricians and Gynecologists, Pittston, Pennsylvania................................................... 72 Jennifer Weiss-Wolf, JD, Executive Director, Birbaum Women's Leadership Center at NYU Law, New York, New York............... 76 Suzanne Silverman Fenske, MD, FACOG, ABOIM, MSCP, Double Board- Certified Gynecologist, Founder, TaraMD, Women's Health Ambassador, HHS Office on Women's Health, New York, New York... 79 Statements for the Record 51& Statement.................................................... 84 American Academy of Family Physicians Statement.................. 89 ABIG Health Statement............................................ 92 American College of Obstetricians and Gynecologists Statement.... 118 Marion Adams Statement........................................... 124 Andrea Giancontieri Statement.................................... 132 Gia Thomas Statement............................................. 137 Hadassah Menopause Statement..................................... 141 Let's Talk Menopause Statement................................... 144 C O N T E N T S ---------- Statements for the Record (cont'd) Page Liz Powell Statement............................................. 146 New York University Grossman School of Medicinie Statement....... 149 National Menopause Foundation Statement.......................... 152 Kimberly Paine Statement......................................... 158 Sharon Carothers Statement....................................... 164 The Pause Life's Statement....................................... 172 HALF THE COUNTRY, ZERO HEARINGS: MEETING THE MOMENT TO END THE MENOPAUSE CARE GAP IN AMERICA ---------- Wednesday, September 16, 2026 U.S. Senate Special Committee on Aging Washington, DC. The Committee met, pursuant to notice, at 3:27 p.m., Room 216, Hart Senate Office Building, Hon. Rick Scott, Chairman of the Committee, presiding. Present: Senator Scott, Moody, Gillibrand, and Kim. The Chairman. The Special Committee on Aging will now come to order. As Chairman, I am proud of this Committee's long history of working together on a bipartisan basis to address topics that impact aging Americans. Today, we continue this tradition with Ranking Member Gillibrand chairing the first ever congressional hearing focused on menopause. I now recognize Ranking Member Gillibrand for her opening statement. OPENING STATEMENT OF SENATOR KIRSTEN E. GILLIBRAND, RANKING MEMBER Senator Gillibrand. Thank you, Mr. Chairman, for giving me the opportunity and the opportunity for all of us to have this hearing. I am super excited. It is one of the most under- researched, under-treated, and under-discussed topics. We call it the menopause care gap and thank you to the witnesses for sharing your experiences and expertise today. We are very excited to hear from you. Seventy-five million American women are in perimenopause, menopause, or post- menopause right now. Congress has never held a single hearing on the gaps in care that they face, and that changes today. Menopause affects half the population. For generations, women have been told to suffer in silence. I am done with silence. Menopause affects half of the population, and this is something that we have to address. The neglect of menopause research, education, and treatment is a health care failure, an economic failure, and a policy failure. While medical education continues to evolve, previous studies have shown 80 percent of OBGYN residents say they are unprepared to talk about menopause. Eighty percent of the doctors that are supposed to be the most knowledgeable say they are unprepared to talk about menopause. Fewer than one-third of residency programs teach it at all. Three out of four women who seek care for symptoms leave untreated. That is unacceptable. We have made great advances in treating symptoms, but access remains a significant barrier. Whether it be misleading labels, insurance not covering it, or patch shortages, it is clear women are not getting the care that they need. The cost is enormous for women and the economy. The Mayo Clinic puts the price of menopause in the United States at $26.6 billion per year. $1.8 billion of that is lost work time alone. As many as one in ten women leave the workforce because of menopause. They walk out at the peak of their careers and take decades of knowledge and experience with them. It is a tragedy, and it is avoidable and the Federal Government has never adequately funded the research that could fix it. We need a comprehensive strategy to prioritize midlife women's health in research, like the one in the bipartisan bill that Senators Murray and Murkowski lead. Research is the foundation. It drives clinician training, better information, and evidence-based treatment for patients. We also have to make sure women can actually get in the door. The average wait time to see an OBGYN in this country is over a month. In rural communities, it is longer. For women who have been experiencing debilitating pain, heavy bleeding, and symptoms she can't explain, a month is far too long. We must strengthen this workforce facing critical shortages and make sure it is ready when patients arrive. To do that, we need to know where to start. I am proud to lead a bipartisan request to the Government Accountability Office alongside Chairman Scott, and members of this Committee. It will tell us what the Federal Government actually does on menopause, how well our doctors are trained, and where the gaps are. You can't fix what you refuse to even measure. Women have carried this alone for generations. Not anymore. We must meet the moment, and I look forward to hearing from our witnesses today and discussing this critical issue. OPENING STATEMENT OF SENATOR RICK SCOTT, CHAIRMAN The Chairman. Thank you, Ranking Member. Thank you for your leadership on this issue. Women make up half of the American population, and eight to ten million Americans experience menopausal symptoms each year. While menopause is a natural part of aging for women, every woman is impacted differently and more often than not, they are not simply dealing with a minor inconvenience. They are facing symptoms that have real consequences on their quality of life. Not to mention having to navigate finding a doctor, understanding their symptoms, developing a treatment plan, and managing changes to their health, all while balancing jobs, families, and everything else life throws at them. That is unacceptable. Women should not suffer in silence. Too often, women still enter this stage of their lives without the information they need or clear understanding of what to expect and then they are focused--they are forced to figure out as they go through it. There is simply no excuse for the lack of resources and information to help every woman navigate menopause and the challenges that come with it. The hearing is not about a one-size fits all solution. It is about ensuring that every woman in this country has access to good information, the right health care provider, and treatment options, so they can advocate for themselves and make the best decisions for their health. To empower women with information so they can be the best advocates for their help, we must first identify the gaps. That is why I am proud to work with Ranking Member Gillibrand on a letter to the GAO asking them to identify gaps in menopause research and care. We also need providers who have most up to date training, who are able to clearly discuss treatment options with their patients. Right now, women have several treatment options at their disposal to manage symptoms, including hormone replacement therapy. For years, however, questions and concerns about the safety of hormone therapy and the FDA's black box warning on these products left women and doctors unsure how to proceed. Thankfully, we now know that hormone replacement therapy is a safe option for many women. Still, access barriers like lack of information and limited availability can make it difficult for women to access these medications. I applaud the FDA for improving access to menopausal treatment by taking steps like removing the black box warning on hormone replacement therapy treatments and empowering women to make the best decision for themselves and their health. Following the FDA's removal of the black box warning last November, the data is already showing that women are using treatments like hormone replacement therapies and estrogen patches more. Treatment is a huge piece of the puzzle, but the shortage of health care providers creates barriers to accessing it in the first place. There are simply not enough specialists to meet the growing demand. Approximately two million women enter menopause each year, and the number of residents and physicians is not keeping pace with the aging population. These shortages result in a lack of access and physician burnout. The doctors we have are facing tremendous pressure. More than 45 percent of OBGYNs have reported experiencing burnouts. Just earlier this year, this Committee had a hearing where we heard firsthand about this happening. Congress should look at what we can do to eliminate unnecessary regulatory barriers and administrative burdens that take doctors away from the patients and contribute to burnout. Every woman has a difficult journey--has a different journey, and difficult--with menopause, and menopausal can have a wide range of effects, which is why it is so important that women have access to providers and treatment. Changes in hormone levels associated with menopause can affect bone, heart, and other aspects of women's health, and appropriate treatments can make a real difference in women's symptoms and quality of life. Hormone replacement therapy not only helps women manage their menopause symptoms but can also improve their quality of life post-menopause. America has incredible doctors, nurses, researchers, and treatments. Our job should be to make sure women know what options are available, have good information, and can get the care they need. Today's hearing is an important first step in how we talk about menopause and women's health in Congress. I am proud to bring awareness to it with the members of the Committee. I want to again thank my colleague and Ranking Member, Gillibrand, for leading on this issue. This affects so many Americans and I look forward to today's discussion. I think I will turn it back to Ranking Member Gillibrand and she will introduce our first three witnesses. Senator Gillibrand. Thank you, Mr. Chairman. Our first witness, is Dr. Jean Wactawski-Wende. Dr. Wactawski-Wende is the Dean and SUNY Distinguished Professor at the School of Public Health and Health Professions at the University at Buffalo. There she leads the Women's Health Initiative Northeast Regional Center and conducts research on factors influencing women's health. Previously, she served as the Chair of the WHO Steering Committee and has served as Principal Investigator on dozens of NIH funded research studies. She brings 40 years of experience in women's health research to our discussion today. You may begin. STATEMENT OF JEAN WACTAWSKI-WENDE, PH.D, DEAN AND SUNY DISTINGUISHED PROFESSOR, SCHOOL OF PUBLIC HEALTH AND HEALTH PROFESSIONS, UNIVERSITY AT BUFFALO, BUFFALO, NEW YORK Dr. Wactawski-Wende. [Technical problems] Chairman Scott, Ranking Member Gillibrand, and honorable members of the Senate Special Committee on Aging, thank you for this opportunity to testify today on one of the most important and historically overlooked issues in American health care, the health of women as they age, particularly during the menopause transition and the decades that follow. I am Jean Wactawski-Wende, an epidemiologist whose research has focused on women's health for more than 40 years. I serve as SUNY Distinguished Professor and Dean of the School of Public Health and Health Professions at the University at Buffalo. Since 1993, I have been a funded investigator in the Women's Health Initiative, one of the largest and most influential studies of women's health ever conducted. WHI enrolled more than 161,000 post-menopausal women across the United States to study the effects of hormone therapy, diet, and calcium, and vitamin D supplementation on the major health outcomes in older women, including heart disease, cancer, stroke, osteoporosis, cognition, and mortality. Three decades later, nearly 40,000 participants remain actively engaged in this study. Their contributions have transformed our understanding of women's health and have helped millions of women make more informed health decisions. Menopause, as you said, Senator Gillibrand, is experienced by approximately half our population, and more than one million American women enter menopause each year. Today, about 64 million women 50 or older are postmenopausal, and that number is expected to exceed 80 million by 2050. These women represent one of the fastest growing segments of our population, yet many of their health needs remain inadequately studied and addressed. I will highlight four priorities that deserve national intention. First, we must increase investment in funding research on women's health across the lifespan. Women's health research, particularly in older women, has been underfunded. We need studies that further examine how hormonal changes across the lifespan influence healthy longevity. Women are not simply smaller versions of men. Biologic differences matter, and understanding those differences is essential for developing effective prevention and treatment strategies. Second, we must address the growing burden of chronic disease in aging women. The greatest health challenges facing older women include cardiovascular disease, dementia, cancer, osteoporosis, and frailty. Women account for the majority of Alzheimer's disease cases in the United States, and heart disease remains the leading cause of death in women. Cancer survivorship is increasing, but many survivors face long term effects of treatment that impact independence and quality of life. Healthy aging must focus not simply on extending life, but on preserving function and independence. Third, we must improve education and clinical care for women after menopause. Many women report difficulty obtaining accurate information and evidence-based care. Menopausal symptoms can significantly affect quality of life, yet many clinicians receive limited formal training in menopause management. Women deserve access to health professionals who are informed by the latest science and can provide individualized evidence-based health recommendations. Fourth, we must recognize the importance of healthy behaviors across the life course. Nutrition, physical activity, smoking avoidance, sleep health, mental well-being in women at younger ages influence their health decades later. Investments in prevention beginning early in life can reduce chronic disease and frailty at later ages. We know that events women experience in pregnancy can be associated with related health outcomes as they age. We have learned a lot about health and women's health from WHI, and WHI opened many new questions. In 1993, I helped to launch WHI when I was a new mom of a young daughter. Today, I am the grandmother of a 10-month-old granddaughter. Like millions of American families, I want the women in her generation to have access to the evidence, care, and opportunities needed to live long, healthy, and independent lives. Health of aging women is one of the greatest public health challenges and opportunities of our time. Thank you both for your leadership and commitment to advancing women's health. I welcome your questions. Senator Gillibrand. Thank you. I now want to introduce our next witness, Ms. Jennifer Weiss-Wolf. Ms. Weiss-Wolf is--oh, I skipped one. I want to introduce our next witnesses, which is Dr. Lynne Coslett-Charlton. She is a board certified Gynecologist and American College of Obstetricians & Gynecologists District III Legislative Chair, where she leads regional legislative efforts while specializing in minimally invasive and robotic assisted surgical procedures. Previously, she served as Administrative Chief Resident at Pennsylvania Hospital of the University of Pennsylvania and currently serves on the American College of Obstetricians and Gynecologists. STATEMENT OF LYNNE M. COSLETT-CHARLTON, MD, FACOG, MSCP, GYNECOLOGIST, AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS, PITTSTON, PENNSYLVANIA Dr. Coslett-Charlton. Good afternoon. My name is Dr. Lynne Coslett-Charlton. I am a private practice gynecologist who has been serving my community in Northeastern Pennsylvania for the last 27 years. I am Fellow of the American College of Obstetricians and Gynecologists, or ACOG, which has a membership of more than 60,000 physicians and partners specializing in and dedicated to advancing women's health. Thank you to Senator Gillibrand, Senator Scott, and the Special Committee on Aging for holding the first hearing on menopause, and your efforts to close the gap in menopausal care and improve the quality of health for mid-life women. OBGYNs like myself care for women throughout their entire life cycle, from adolescence through pregnancies, the perimenopausal and menopausal transition, and the post- menopausal years. Over the years, my patients have entrusted me through their surgeries, delivering their children, screenings for cancer, and contraceptive counseling. Like my colleagues, I cherish the relationships with these patients, and I have had the privilege now of navigating menopause with many of them. Menopause is a normal, expected stage of life marked by the permanent end of menstruation, typically occurring around age 50. Women may spend, like we said, nearly half of their lives in the perimenopausal and postmenopausal years. The menopausal transition, or perimenopause, typically begins in mid 40's and brings significant hormonal changes that can affect a woman's health and well-being. My patients experience a wide range of symptoms during this transition, including hot flashes, vaginal dryness and atrophy, difficulty sleeping, altered mood and metabolism, and other effects of hormonal change. For some women, these symptoms can be debilitating, interfering with daily routine, work, and overall quality of life. Yet, many women face substantial barriers to obtaining timely and effective menopause care for their symptoms. Underinvestment of women's health research, physician shortages, especially in rural areas, and inadequate health insurance coverage can create significant barriers to care, which are even more burdensome for underserved and low resourced communities. Despite the challenges, there are some reasons to be optimistic. The FDA's removal of the box warning on estrogen therapies was a huge step in the right direction for improving access to care. For years, that box warning did not reflect the accumulating scientific evidence and discouraged patients and clinicians from using an effective treatment. I have seen this in my own practice. While this move was long overdue, especially for low-dose vaginal estrogen treatment with an overall very high safety profile, it does have some nuances. Menopause care is not a one-size fits all. For some patients, systemic hormone therapy may come with an increased risk, emphasizing the importance of access to an individualized, thoughtful approach to menopause management based on each patient's unique risk factors. Moving forward from the seismic change, further research into effective treatment options will lead to better and more individualized care. By nature, scientific discovery is fluid, and so is medical training. When I trained, I was fortunate to receive training in menopause care from excellent leaders in menopause science and left residency equipped with the tools to provide comprehensive care to midlife women. This was pre-WHI. More research leads to a better prepared physician workforce. In response to new evidence and discoveries, medical education, residency training, and continued education programs for practicing physicians evolve. Increased public awareness and efforts to de-stigmatize menopause will lead to better outcomes. I am encouraged by the positive improvements in public perception of menopause treatment. Celebrity voices and social media have helped to normalize menopause and have empowered women to recognize that their symptoms are common and treatable. Unfortunately, however, social media has also become a vehicle for misinformation. Menopause has become big business, and many women are turning to influencers rather than trained clinicians for advice. Much of my time is spent counseling patients about different supplements and unregulated products marketed online on different platforms. This is why ACOG and other organizations have invested in education to direct patients to safe, evidence-based, and medically appropriate care. Fortunately, there is a path forward. ACOG supports Senator Murray's Advancing Menopause Care and Midlife Women's Health Act to strengthen and expand federal research, health care workforce training, awareness and education efforts, and public health promotion and prevention activities. Alongside advocacy and opportunities like this hearing, together we can make serious progress for my patients and for all midlife women. Thank you for having me here today, and I look forward to your questions. Senator Gillibrand. Thank you. I now would like to introduce our next witness, Ms. Jennifer Weiss-Wolf. Ms. Weiss- Wolf is the Executive Director of NYU Law's Birbaum Women's Leadership Center, where she works closely with leaders and advocates to pursue policy reforms related to menstruation and menopause. Previously, she authored a Citizens' Guide to Menopause Advocacy and has presented testimony on legal policy before Congress, the White House, and State Legislatures across the country. You may begin. STATEMENT OF JENNIFER WEISS-WOLF, JD, EXECUTIVE DIRECTOR, BIRBAUM WOMEN'S LEADERSHIP CENTER AT NYU LAW, NEW YORK, NEW YORK Ms. Weiss-Wolf. Thank you, Chair Scott, Ranking Member Gillibrand, and members of the Committee for convening this historic hearing. I am Jennifer Weiss-Wolf, and as you said, my work focuses on menstruation, menopause, and the law. It is an uncommon sphere of expertise, I know, but these are universal experiences for half the population that too often go neglected and are deserving of public policy attention. I am here today for two reasons. First, to help shine a light on the challenges millions of women in the United States experience throughout menopause and second, to describe policies that can help course correct. Federal agencies like the FDA, as well as state governments, including both of your home states, are already stepping up. None of that is a substitute for the authority of Congress and the impact that you can have on moving the needle nationwide. I am not a doctor, and I leave the medical expertise to my fellow panelists, and I second the jarring statistics about lack of research, training, and awareness that Senator Gillibrand and Scott have already put forth, but numbers can't fully capture the depths of frustration so many women encounter. I often think of my friend, Dr. Rachel Rubin, who is a board-certified urologist here in D.C. at Georgetown and she addressed HHS this morning on menopause issues. When Dr. Rubin's comatose immunocompromised mother was in immediate danger of going into urosepsis, the ICU denied Dr. Rubin's request to prescribe vaginal estrogen, incorrectly claiming it would cause blood clots. After Dr. Rubin eventually secured a prescription, the pharmacist refused to dispense it, citing the mere existence of its longstanding, inaccurate warning label, which as people have mentioned, gratefully the FDA removed and rewrote earlier this year. If this is how hard an expert had to fight to get an urgent prescription filled, that speaks volumes about what the rest of us face. What kind of policies can Congress advance to make real- time changes? I have a few suggestions. Number one would be to please fund a modern research agenda. Less than one percent of federal research funding goes to menopause and midlife women's health. We have not studied women who started taking systemic menopausal hormone therapy and perimenopause, or who stayed on it continuously from their 50's through their 60's. Modern clinical trials that include millennial women and Gen X women, diverse racial, ethnic, and geographical representation, and data collection and symptom tracking using modern technology, all of that is sorely needed. We especially deserve to know if there are preventative benefits to our chronic brain, bone, and heart health. To that end, women in the U.S. are two-thirds of all Alzheimer's cases, yet only 12 percent of NIH funding for Alzheimer's and related dementia research is focused on women. Might estrogen support cognitive function? Please don't look at the daily headlines, especially this past week, because you will see 100 different answers. We deserve gold standard clinical trials and I can't help but add that there has been no shortage of studies on Viagra's link to lower risk of Alzheimer's for men. There are three current federal bills that all aim to increase research that you should support, the Advancing Menopause Care and Midlife Women's Health Act, the Service Women and Veterans Menopause Research Act, and the Hormone Health Data and Research Act. The second policy priority would be to improve education. There is consensus that the medical establishment does not adequately educate future and current doctors about menopause, and that is not just OBGYNs and internists, but includes cardiologists, orthopedists, endocrinologists, urologists, neurologists, oncologists, all the specialists we may see. Congress can intervene by getting behind the Menopause Education for Medical Students Act introduced in the House, and also pushing Medicare and the Departments of Defense and Veterans Affairs, which have control over funding for graduate medical education to ensure that menopause education is part of the accreditation standard. States have already begun addressing this too. They have been incentivizing, through their state medical boards, to include menopausal in continuing professional education for clinicians. The third policy area that requires your attention is ensuring affordable, accessible care and treatments. Menopause prescriptions can be pricey. A monthly supply of systemic hormone therapy will run over $100. I am just telling you, mine is $75 with insurance, and that is when I can get it, which is few and far between these days, thanks to the alarming short supply of estradiol patches and I will share, too, that my copay has tripled, because I can only get a one-month supply now with the same single copay. Non-hormonal treatments for hot flashes are even more expensive and not covered by insurance, and these are not covered regularly by Medicare or Medicaid. Louisiana was the first state to mandate that its own state Medicaid and insurance programs in the state mandate menopause treatments, and six other states have followed suit. Fifteen years ago, Representative Barbara Lee from California introduced the Menopausal Hormone Replacement Therapies Act in Congress for 2011. Please resurrect that. I want to just give two quick closing thoughts from the advocacy trenches. Please know that there are so many brilliant people making massive contributions every day in medicine, in innovation, in philanthropy, who are ready to stand with you in pushing for bipartisan reforms. Second, if you have seen a headline or two or ten saying menopause is having a moment, it most definitely is, but it is not a moment--it is here to stay and just ask all the loud millennials standing behind me. This proud Gen Xer wants to thank you for holding this hearing, and I look forward to working with you in the future. The Chairman. Well, first off, thanks for the witnesses. Now, I will introduce our last witness. Dr. Suzanne Fenske is a double board certified Gynecologist and Founder of TaraMed, MD, a women's health practice in New York City that specializes in integrative gynecology, functional medicine, menopause, hormone optimization, and longevity medicine. She is also a health Ambassador for the U.S. Department of Health and Human Services Office on Women's Health and has worked to raise awareness of menopause and other women's health issues. Thank you for being here. Please begin your testimony. STATEMENT OF SUZANNE SILVERMAN FENSKE, MD, FACOG, ABOIM, MSCP, DOUBLE BOARD-CERTIFIED GYNECOLOGIST, FOUNDER, TARAMD, WOMEN'S HEALTH AMBASSADOR, HHS OFFICE ON WOMEN'S HEALTH, NEW YORK, NEW YORK Dr. Fenske. Thank you, Chairman Scott, and Ranking Member Gillibrand, and members of the Senate Special Committee on Aging for the opportunity to testify today. I am here both as a provider and as a mid-life perimenopausal woman navigating the health care system. When I ask patients what they hope to get from their care, I often hear, I want to feel like myself again. I understand this because I felt it myself. The unfamiliar anxiety, irritability, insomnia, hot flashes, night sweats, brain fog, difficulty doing work, and loss of interest in things I once enjoyed. Access to appropriate menopause care can help women regain that sense of self. That is what is at stake for women we are here to represent. I present to advocate for greater investment in women's health research, education, and prevention across the lifespan, but particularly perimenopause, menopause, and the postmenopausal years. My own OBGYN education was focused largely on reproductive issues and pregnancy. I received very little menopausal training in my core curriculum. Every day I see how women's concerns, and especially midlife and older women, have fallen through the cracks of our health care system. Menopause care isn't just about managing symptoms, although that is important. Menopause is a turning point, and therefore a great window of opportunity for a woman because this phase shapes a disease risk and health for the rest of her life. Before menopause, a woman's risk of chronic disease is typically lower than a man's, but after menopause, her risk significantly increases. To name just a few, heart disease, hip fractures, and urinary sepsis as causes of death in older women. Heart disease remains the leading cause of death for women. The loss of ovarian hormones with menopause increases the risk for heart disease because of changes to body compositions, lipids, insulin sensitivity, and blood pressure. However, HRT initiated around the time of menopause or within 10 years reduces cardiovascular disease, and all-cause mortality. Treatment decisions require individualized assessment and benefits and risks. Recent outpatient data shows HRT use in approximately seven percent of women ages 45 to 54. We need to understand how much unmet need remains and address the barriers that prevent women from receiving appropriate care. Women have almost three times as many hip fractures as men. By age 81, one in five women will have a hip fracture. By 90, one in two. Twenty percent of those women will die within one year. Bone loss accelerates around menopause, which occurs on average age about 51. Routine bone density screening starts at 65. Early risk assessment and prevention are essential. We are missing a huge opportunity for prevention, and HRT can prevent bone loss and osteoporosis related factors when initiated around menopause. While some menopausal symptoms may improve after the menopausal transitions complete, other symptoms such as vaginal and urinary symptoms, including urinary tract infections, often get worse. These symptoms are part of the larger condition, genital urinary syndrome of menopause, which affects 84 percent of women. Recurrent UTIs in older women are particularly dangerous because they can lead to sepsis and even death. In a study of more than 5,600 women with recurrent UTIs, once vaginal estrogen was initiated, there was a 50 percent decline in UTI's. To address these gaps, we need greater investment in women's health research. A National Academy's analysis found that only 8.8 percent of NIH grant spending from 2013 to 2023 focused on women's health research. One area of research that is desperately needed is around breast cancer survivors and the safety and efficacy of HRT. These women are often left out of the HRT conversation and may miss out on the potential benefits for future health and quality of life. We also need more education, both for women so they know what solutions they have and what to advocate for, and for healthcare providers. We currently have a physician shortage and desperately need more doctors trained in providing menopausal care. We also need every other medical specialty to understand how menopause affects what they observe and practice every day. The Government is in a unique position to help with immediate concerns regarding HRT availability. First, we are facing a dire shortage of HRT medications, especially patches and daily gel use. As more women seek menopausal care and choose HRT, we need to meet that demand. We cannot push forward without having the availability of treatments. Second, we have FDA approved estrogen and progesterone, but we desperately need testosterone. It is not just about libido. It also supports mood, body composition, and energy, to name a few. For some women, it is the peace that can finally help them feel like themselves again. As a final thought, as we fund more women's health research and train more doctors, we need to be thinking about prevention. As physicians, we learn how to treat heart disease and osteoporosis once diagnosed, but it is a different skill set to catch a disease at its earliest stage or even prevent it. How we address menopause is an incredible opportunity to improve vitality and quality of life for women as they age, which I would argue benefits all of society. Prevention of disease improves quality of lives, saves lives, and lessens economic burden. I would like to thank the Senate Committee for this opportunity, and I look forward to continued collaboration on this mission to advance women's health care. The Chairman. Thank you, Dr. Fenske. Let's start with the Ranking Member, if you want to start asking questions first. Senator Gillibrand. Thank you. I would like to first address the barriers to treatment. Despite limited federal investment in menopause and midlife women's health research, we have made great advancements in treating symptoms of menopause, particularly with hormone therapy. However, many women still cannot access the care that they need. Dr. Coslett-Charlton, from your perspective as a clinician, what are the most significant barriers impacting women's ability to access treatment, and how does that change based on where they live? Dr. Coslett-Charlton. In my practice, I treat women with all types of health insurance. We definitely see gaps in the availability and the coverage with those health insurances. Some treatments are covered, other treatments are not. I also see these gaps when providing clinical care. Much of my day is often spent navigating, this will be covered for her, no, this won't be covered for her. I really think about my patients and their out of pocket costs because I am in a community where, you know, every dollar counts to a lot of really hard working women, and the access to barriers with insurance coverage is a big problem. Second of all, recently, I have been finding in my clinical practice that I have to get prior authorization for low-cost, FDA approved hormonal therapy. That is a huge burden on the practice. I have one nurse that does prior authorizations all day. These are well-proven treatments and any efforts that Congress can make to decrease administrative burden for physicians is greatly appreciated. Senator Gillibrand. Dr. Silverman Fenske? Dr. Fenske. So, so many things. First off, what issues remain are that regarding kind of the access, this comes down to essentially initially insurance reimbursement, so there is not much incentive for physicians to take care of menopausal women. The way that they are reimbursed from an insurance perspective, the hospital system can't support, and the private practitioners can't afford to take of menopausal woman for her visit because of the amount of money she is reimbursed for that visit. Senator Gillibrand. Does Medicaid have a better, or Medicare have a better reimbursement rate? Dr. Fenske. Very low reimbursement rate for those codes-- for those code, yes, so for access to it, and then there comes down to the education. When you look across sort of-- unfortunately, you had a wonderful education, but there is no guidelines on the education. When you are an OBGYN resident, you know that you need a minimum of 200 vaginal deliveries to complete your residency. There is no mention of how much education you need on menopause, so you have these residents graduating not being educated. The final issue---- Senator Gillibrand. Who decides those standards? Dr. Fenske. I think it comes down to the ACGME. Senator Gillibrand. How many women are on that board? Dr. Fenske. I am not certain actually. Senator Gillibrand. Dr. Wactawski-Wende, do you have any opinion on access? Dr. Wactawski-Wende. It is not an area that I research, but I do have personal experience and access from family members that describe some of the similar things that happen to women, not enough health care, not enough trained gynecologists that really focus on menopause. I think it really does limit the access of women to get the care they need. Senator Gillibrand. Thank you. Ms. Weiss-Wolf, from your perspective as an advocate and as an author, what are the most significant barriers impacting women's ability to access treatment, and how does that change based on where they live? Ms. Weiss-Wolf. I would say the answer is pretty similar to what the physicians on either side said to me, but I hear it from patients' point of view, and the frustration that they experience. I think that the connection of lack of training and lack of research leads to a variety of conflicting messages that then come down from providers, and people will also be forced to go from doctor to doctor if they don't either hear the answer that they want to hear, need to hear, or that adequately serves them and then that ends up causing additional costs and frustration. Oftentimes, they will wind up in the ER. I mean, when you look at it from the patient point of view, it is the same problem, but it is just how it is experienced. The question about geographic, the relevance of geographic location. Even while there are certainly care deserts in this country, in particular, in the South and the Midwest, even in metropolises where there seems to be, you know, plenty of care, somebody could still have to wait a month, six months, a year for an appointment and one intervention that I think should be high on Congress's list is telehealth. There are opportunities for menopause care and telehealth that I think are unique to the way that that care is provided and telehealth could fill a real gap in terms of concentrating menopause experts. We have to be just very careful that telehealth is accessible to all as well, and that there aren't barriers that are created by connectivity or insurance otherwise. Senator Gillibrand. Thank you, Mr. Chairman. The Chairman. Senator Kim. Senator Kim. Thank you, Chairman and I just want to thank the Ranking Member as well for just your leadership and giving us a space to be able to talk about menopause, talk about this in a form that often hasn't happened here in the Senate or on Capitol Hill as a whole, so your leadership is much appreciated. I wanted to just dive into a few different angles of this. Ms. Weiss-Wolf, I would like to just start with you. Just, I am grateful for just the record that you have been able to produce of just these testimonials and statements from many different women and I guess I wanted to ask you about the impact on women's work experience and the challenges on that front. This is something I am hearing more and more of as my generation is growing older, of just women uncertain how to be able to balance their careers, especially as we are often getting into, hopefully, the heights of our careers in these ages but then also understanding, you know, their own challenges when it comes to their perimenopause, menopause. Some of the difficulties in terms of being able to understand how that intersects with it. Also workplaces and oftentimes bosses and others maybe not understanding the needs that women might be having through those transitions. I want to just hear--is that something that you heard about as you were-- as you have been documenting this and engaging with women? Are there, you know, certain types of workplace or policy changes that you think would be having the greatest impact on reducing absenteeism, turnover, wage loss, and other challenges that women might be facing? Ms. Weiss-Wolf. Thank you for the question, Senator Kim and your home State of New Jersey is also a leader in the menopause front. The workplace is a really interesting issue to me because, yes, it is true that women would be at the prime of their leadership in terms of income, in terms of influence, and in terms the way that they create, you know, a chain of success for others, their mentorship capacity on institutional knowledge and skill that they have. There have been a wide variety of workplace accommodations and benefits that private sector employees have sought to bring about. They do see how popular the menopause discourse is, and I think want to intervene with some of the best intentions. We have also heard the, you know, the economic analysis too about what is lost when we don't try to keep women in the workplace and support them during this stage. I will say that I actually harbor some real concerns about those accommodations and those benefits even done with the best intentions because right now, we certainly do not have federal anti-discrimination protection should somebody choose to take their employer up on those benefits. Some states, both Illinois and Rhode Island, have actually passed laws that both require that the accommodations follow suit with how pregnancy accommodations are provided, and similarly provide that anti-discrimination protection but without that, I am actually very lukewarm about workplace benefits and---- Senator Kim. Because of the lack of federal protection? Ms. Weiss-Wolf. Primarily because of the lack of federal protection. That would be the biggest reason. The secondary reason would be, as my fellow panelists have said, menopause is not a one-size fits all circumstance. Most of the reforms are focused on very narrow circumstances, whether it is, you know, a little bit of flex time or a cooling room opportunity. These are things that really would only benefit a very small amount of symptoms, a very smaller amount of employees who work in an office environment, not the wide variety of ways people work today and they certainly don't address the long- term health consequences that we think about when we think about menopause. I would far rather see CEOs and business leaders investing in the research and investing in the other kinds of systemic reforms that we need than putting a few Band-Aids in their workplace. Senator Kim. That is a helpful perspective. I wanted to just turn to Dr. Coslett-Charlton. Something that, again, I feel like I am hearing more and more from women of my generation, friends, and family, but a real limited understanding about perimenopause and just understanding and trying to understand, you know, physical, cognitive, emotional symptoms. I know that they can vary quite wildly, but that transition is one that I think has been catching people off guard and uncertainty about this. I guess I wanted to ask you, how can we raise awareness when it comes to perimenopause, that transition, and into full menopause of people who are experiencing it so they can try to recognize symptoms and try to understand where they might fall within that? Dr. Coslett-Charlton. I think one of the things we were highlighting was that a lot of social media awareness is out there, and menopause is definitely having a moment and one of my patients came in the other day, in her mid 20's, and she was asking me a lot of questions that had to do with typical perimenopausal symptoms, and I thought it was a little bit odd. I am like, are you experiencing any of these? She is like, no, but perimenopause has a vibe, and I want to be ready. The discourse, having hearings like this, having this discussion, is really empowering women to take care of themselves, and I think that is really wonderful. I think channeling that energy by increasing physician workforce, increasing patient access to physicians to give them their medical advice is really, really important. The other thing I want to note is that a lot of times perimenopausal symptoms can mimic symptoms of natural disease and even though perimenopause is normal-- a lot of women deserve a workup. I think sometimes the frustrations that patients feel and that they don't feel like they are quite being heard, but it might be because they are being worked up for more serious medical conditions that can have a greater impact on their quality of health care and their quality of life. I think--you know, I think empowering women is a really important thing and educating women, and I really think there is a lot of positive discourse happening right now, and that is exciting. Senator Kim. Yes. No, thank you and as I just wrap up here, as someone who is also trying to learn up and have a deeper understanding, both personally within my own family, but also in the work that we are doing here, I think what I am trying to get a deeper sense of is, what is it that is a lack of awareness that we need to continue to educate, and what is a lack a research, a lack of knowledge and understanding? Where do we need to be doing more testing, more research on links. You know, I am somebody that has been doing a lot of work on cognitive decline. My father has Alzheimer's. A lot of issues of dementia. We see, you know, significantly increased rates of Alzheimer's and dementia with women. You know, are there linkages there in different ways that we need to be exploring further when it comes to menopause or other types of linkages with other types of ailments? You know, that is something that--I am glad we are having this hearing because it certainly is focusing it for me as I try to think through what is the way in which we need to make sure we have the knowledge base to be able to build off from, so just very grateful for the Chairman, for the Ranking Member for holding this, and we will make sure that we continue to followup. Thank you. The Chairman. Thank you, Senator Kim. Dr. Fenske, what is the link between menopause and longevity, and how can treatments like hormone replacement therapy help protect women from chronic disease? Dr. Fenske. Thank you, Chairman Scott, so the link is that basically we know the benefits of, if we use, for example, HRT. The benefits in hormone replacement therapy, as I mentioned, decrease the risk of cardiovascular disease, diabetes, colon cancer, osteoporosis, and there is a 30 percent reduction in all-cause mortality if you are on hormone replacement. It is innately linked to longevity to be on hormone replacement therapy. If women are spending one-third of their lives without those hormones and having that impact, we start to see those changes as practicing medicine. You start to LDL cholesterol start to rise. You start to see insulin resistance start to happen, regardless of their diet and their exercise. You start to their blood pressure start to raise. From a cardiovascular standpoint, the vessels start to harden without estrogen. It increases the pliability of it, so hormone replacement therapy is linked to longevity. The Chairman. You talked about the importance of lifestyle interventions like diet, sleep, and exercise. How can these help women during this process in addition to medical treatment? Dr. Fenske. The most important part--obviously I am biased in that I am an integrated physician, double boarded, but the most important is you have to look at the whole thing, so hormone replacement therapy in and of itself is not going to completely rectify the picture. They have to be educated on proper nutrition, appropriate amounts of protein, fiber, and then exercise I think is one of the most important things that we can do and that previous generations were not as focused on doing. If you want to stay out of the nursing homes, we need to exercise and exercise starting young and consistently. With strength training, cardiovascular, as well as things such as yoga, because it improves balance and stretching. The Chairman. Why is the type of hormone therapy used so important for treating the symptoms of menopause? Dr. Fenske. I am so sorry, can you just repeat the question? The Chairman. Why is the type of hormone therapy used so important for treating the symptoms of menopause? Dr. Fenske. That is the big question too. When we talk about all the studies that we have on hormone replacement therapy, we are sort of lumping all these different hormones together. It is very nuanced. We have to start to differentiate between transdermal estrogen versus oral estrogen. A lot of the data in trials we have, for example, on potential increased risk of dementia, which is questioned--in those trials, that was oral estrogen. Oral estrogen is the one that has a small risk of stroke and blood clot associated with it, while transdermal estrogen does not have that same risk. We have to understand the differences between. In addition, when we look at progesterone, which is the bioidentical version of progesterone, what our bodies naturally produce, versus what we used historically, which was progestins, which are synthetic progestin, we can compare the two and know that there is difference. The current studies we have actually are not really looked at bio identically progesterone with bioidentical estrogen. Most of the trials that we have look at synthetic versions of progestins and then we extrapolate that data and assume that it is all encompassing. Even when I deal with insurance companies and I am denied a medication for women, I get calls back from insurance companies say, well, why don't you give them vaginal estrogen? I said, that is not going to help systemically for them. That is only going to help localize symptoms, so even at the level of the insurance company, we need to push for education. The Chairman. What is the value of seeing a functional doctor if you are going through menopause? Dr. Fenske. I identify more as integrative, right, because that is kind of how I do things. From an integrative perspective, when I speak to a woman, I go through all of the pillars of their health. I focus initially on their nutrition. I will go through exactly what they are eating, calculate their ideal protein intake. I go to their exercise routine, meeting them where they are. You are not going to take somebody who has never exercised and give them a stringent exercise plan. Sleep, stress management. Stress management is so important during this part, especially during this point of life. You talk about their sex life, their libido, their orgasms, their supplements, their approach to everything, and what they want. What are their goals for what they what? It is not just about being a physician and saying what you think they should be doing. It is important in knowing what their goals are and what we want out of their life. Really importantly, too, even when we talk about this conversation, which is so important, we have to focus on also, as mentioned, perimenopause, because that is four to ten years ahead of menopause, so even when you are talking about reform in regard to businesses and so on to make it easier, you are taking about a large portion of life that is going to need to have that evaluation. The Chairman. Thank you. Ms. Weiss-Wolf, in your testimony, you mentioned the FDA's recent decision to remove the black box labeling requirement on certain menopause treatments. How has the FDA's removal of the black box warning promoted women's access to treatment, empowered them to make the best decisions for their health? Ms. Weiss-Wolf. Thank you. Yes, so I think it is really important for people to know that that has been a longstanding demand that wasn't new and part of this menopause moment. This is--you know, the label was put on all estrogen products, including localized vaginal estrogen, after the WHI announcement about increased risks of breast cancer and other incidents back in 2002, and the label went on in 2003. Almost immediately there was pushback, at least certainly on the vaginal estrogen, that warning label, that the indications that were put on it, probable dementia, blood clots, etcetera, did not apply to local vaginal estrogens. Again, I am not a doctor, and I am not here to give scientific medical evidence, so I will leave that to the folks on either side of me but as a matter of practice, it was as scary as a cigarette warning label, a skull and crossbones on it. The story of patient after patient was not only was it sometimes challenging for their doctors to prescribe it because they also weren't educated, but the patient would get it and look at it once they had it and say, I don't want to take this, or their spouse would look at and say why are you taking this, and into the trash it would go, so removing that label has been a campaign underway for quite some time. The FDA denied it in 2018. There was also a lack of understanding then of what the product was. They had called it low-dose estrogen versus local and there has been a new education movement and campaign underway really over the past, you know, I would say four or five years. Let's Talk Menopause, on which organization I am on the board, started an education and citizen petition a couple of years ago in 2024 and we were really thrilled that the FDA was willing to take it up this past year and held public meetings and discussions about it last summer, announced that they would be changing the label last November, and then did so this past winter. I couldn't answer for the impact the way that physicians who see patients could, but it is certainly clear that it has changed the conversation. The Chairman. Thank you. Dr. Coslett-Charlton, how has the way we treat perimenopause and menopause shifted and how has this affected how women navigate this time in their lives? Dr. Coslett-Charlton. I think I dated myself when I said that I had good menopause training pre-WHI, because I aged myself with that a little bit. I did have good training, because at that time, about 30 percent of women were taking-- were using hormone replacement therapy, and a lot of the practitioners and my mentors were leading the cause at the time. Quickly and abruptly, as I entered private practice, that changed, and women became scared. Clinicians became cautious and definitely the uptake of hormone replacement therapies specifically really, really declined and over time, we began treating a lot of symptoms of menopause with other treatments that physicians felt comfortable with and that patients felt comfortable taking and a lot it was, as you were speaking, the perception of--you know, I would give the patients a prescription. I documented that--I testified that I have been practicing for 27 years. These women, my patients, know me. Still, they would go home and read the black box or get nervous and not really take the treatment. I think recently, I really believe that there has been a lot of attention to menopause, more reassurance from smaller studies that have given us reassurance on things that organizations like ACOG have reviewed the evidence, and thoughtful people and researchers way smarter than me have come together and issued new guidance where physicians feel comfort in prescribing these medications again. I have had cardiologists actually send patients to me to talk and I think that is really promising to talk about hormone replacement therapy and how it can prevent--potentially prevent heart disease. I think we need more research on that and definitely more clarification. We know it can definitely help longevity and bone health in women and these are things that I think patients are feeling more reassured that they could take the therapies as prescribed. They have more confidence in the therapies as prescribed, and physicians are also, so a lot of the numbers of residency training, I am pretty sure clinically just speaking to my colleagues that that information is increasing. A lot of things that we learn in residency, as Dr. Fenske could attest to also, is a lot our education happens in practice. Things that I did 28 years ago, 30 years ago when I was a resident, innovation, research, practices change, and as lifelong learners and caregivers of women, we need to evolve with that. I think there has been really great resources to do that. ACOG has done a lot of investment. Our recent annual clinical and scientific meeting was standing room only for young fellows and residents for the menopause track. There is a lot more availability for physicians to continue that critical CME to be comfortable prescribing these treatments. The Chairman. Thank you. Dr. Wactawski-Wende, how can treatment lifestyle interventions for women undergoing menopause promote healthy aging and aging in place? Dr. Wactawski-Wende. Certainly we do know that activity, physical activity, getting diets that are high in fiber, low in fat, high in protein, all can be great determinants of what happens later in life. You know, women are complex and have many different health outcomes that occur, but some of those preventive measures that were already discussed, that I mentioned and some of my colleagues, are all important. At this age of menopause, women have about a third or more of their lives still to live and it is a change hormonally that occurs. The menopausal transition occurs, but increases in heart disease and cancer and dementia, frailty, osteoporotic fracture all occur in that time period. Anything we can do to prevent those diseases, I think, is what we should do. I want to go back for a second to the importance of clinical trials, however, because some of the evidence that we are talking about has come from observational studies. Clinical trials are the gold standard of evidence, and we do not have enough of those trials in women, especially in post-menopausal women. WHI was such a trial, and it helped us to understand the long-term benefits and risks of hormone therapy, specifically conjugated equine estrogen and medroxyprogesterone acetate at doses that were common in 1993. Now, since WHI's results, the type of formulations and the doses have decreased quite a bit, but we have not done the clinical trials to look at the health outcomes of those changes and I think women deserve to have that done to be able to give all our clinicians the evidence to say what are the risks and benefits. I am not aware--in WHI heart disease was not prevented and in fact, in the first two years of that study, there was an increase in heart disease observed. There was a similar study done before WHI, the HERS study that was looking at secondary prevention of heart disease, and in that study as well, in the first two years, taking conjugated equine estrogen and medroxyprogesterone acetate increased the risk of heart diseases, so there are nuances. I do believe lower doses and other formulations may have less risky profiles, but we have got to do the science to be able to say exactly what those risks and benefits are. I am advocating for more clinical trials, more research to help women make the most informed decisions. The Chairman. Thank you. Let me turn it back over to Ranking Member Gillibrand. Senator Gillibrand. Thank you, Mr. Chairman. There is a lot I want to talk about. We don't have all night. I do want to expand on the research. If you could have unlimited dollars to do unlimited research, where would you focus your effort, Dr. Wactawski-Wende? Dr. Wactawski-Wende. I think we are here right now to talk about menopause, and I still believe many of these questions that I have talked about have not been answered in relation to hormone therapy and long-term risks and benefits. We already know that hormone therapy is beneficial for treatment of menopausal symptoms. It was not the question we asked, but should we be taking hormones longer than the menopausal transition? What are the risks and benefits of lower doses, different formulations? That still is unknown. I am a dean of a school of public health, and I do believe in prevention, primary, secondary, and tertiary prevention. Anything that we can do to help women to live longer and healthier lives. The women we talk to in WHI, one of their primary concerns is being at home, staying at home as they age, having independence. Two of the major issues that we are managing and that seem to be of concern are mental health and cognition as we age, and what we can do to prevent those conditions. We need more clinical trials that look at interventions that can delay declines in both and also, frailty. Senator Gillibrand. I also don't think we have any solutions for something that Dr. Silverman Fenske mentioned, which is the challenge that older women, particularly women in their 70's, 80's and 90's with urinary tract infections, because every woman in that age group, they suffer recurring infections over and over and again, and they are sometimes deadly. They go untreated and it is typically given the back of the hand by the medical profession with, oh, it is just hygiene. It is not. It is something much deeper and more complex because it is a constant recurring phenomenon and so, vaginal estrogen may be a solution to help that, but are there other solutions? I don't know, but I don't think we spend any time researching women's health once they hit 70. We are begging for dollars when they are in their 40's, and their 50's, and their 60's, but I can promise you there is zero for 70's and 80's. I do think we need research there. I also think we needed research for people who have had breast cancer. I do a lot of work to get young women to do their own exams, and to lower the age for mammograms because we are seeing more women in their 20's and 30's now getting breast cancer when the recommendation is you don't start mammograms until you are 40. Well, you are dead because you didn't catch it in your 20's or 30's, and you weren't educated about how to do that and so, we spent a lot of time focusing on breast cancer, so the number of women in my cohort who have had breast cancer is shocking of just women I know and so, if they aren't able to use patches or creams or gels, so they can't have systemic hormones, and they can do localized hormones if needed, but what are the solutions for them? We haven't talked about any solutions outside of hormone replacement therapy and if you are talking about X percentage of women who can't take that because it increases their breast cancer risk, or it makes their breasts denser, or it gives them breast pain, these are issues that we are not even mentioning and I know a lot of women who suffer from those types of things. We have not mentioned the women who have severe bleeding, who have fibroids, who have to have hysterectomies. Like the amount of medical challenges that hit women going through menopause are so numerous, we have barely scratched the surface and so, the common understanding of menopausal is, oh, you get hot flashes, oh you might not sleep well, oh, yes, deal with it, so because we don't talk about the fact that 50 percent of women can't have sex because it is so painful, that is 50 percent of women. How much money do we spend investing in Viagra for x percent of men who need support? Have we done any investigation for 50 percent of women who might need support? Probably not, so that is one symptom. I have not heard anything about, what do you do with the fibroids and with---- The Chairman. I think that is important research, by the way. Senator Gillibrand. Well, you would as a husband, I am sure but, and the last point I want to bring up, I want to bring up the myriad of symptoms. How do they affect women in the workplace? I want talk about women at the height of their careers. You are 40. You are just making partner at that big law firm. You have just gotten your MD. You are starting your practice. You are running a small business. You are getting your kids off to school and you can finally focus on your career. Those years are being undermined by lack of medical treatment for the symptoms in the 40's, the symptoms in the 50's, symptoms in 60's, and into retirement. I would like to talk about that, and I would you each from your own experience from being a doctor, or a patient advocate, or a researcher to tell me what is the economic drag on America because we haven't spent enough time focusing on how to treat women's health for several decades of their life and during the decades of their highest earning potential. What are the type of symptoms that are debilitating? What happens to women in midlife that derails them? I would like to know what percentage of divorces are caused because we just didn't treat women's medical needs at the age of 40 and up? Probably a very high number. How many economic changes have women had to go through because of unforeseen divorce, or unforeseen medical problems, or breast cancer and not being able to treat these symptoms because there is no medicine at all? Please talk about that. I want to hear about what is the impact on America because we refuse to study women's health after the age of 40? You can start, Dr. Silverman. Dr. Fenske. Thank you. Thank you for bringing that up. Thank you, so of course talk about the benefits in regards to health, but yes, 100 percent. To really focus in on what the symptoms are and what women are experiencing, and what I talked about with the four to ten years of perimenopause, so we are not talking about a few months of a woman's life that she is going to white-knuckle through. The mood symptoms are debilitating for women. I have gotten calls from CEOs from a bathroom crying hysterically that they are about to go into a meeting, and they cannot get through it. The brain fog, the cognition. How many women come to me saying, I think I have dementia now. I can't remember anything. Senator Gillibrand. Anxiety. I have read about anxiety. I have read about---- Dr. Fenske. The anxiety is debilitating. The sleep. They are having issues falling asleep. They are waking up. If you speak to any woman, 3.00 o'clock in the morning, they are up, or early morning wakings. They can't consistently sleep, so these things are completely impacting their ability to focus on their jobs, their families, their relationships, and just navigate through a day. Senator Gillibrand. Doctor--or Ms. Weiss-Wolf? Ms. Weiss-Wolf. Not doctor. [Laughter.] I am trying to make that very clear. Senator Gillibrand. Smart woman, Weiss-Wolf. [Laughter.] Ms. Weiss-Wolf. I will take that. Thank you. I mean, this also speaks to the research question, because the question you are asking is almost rhetorical. What do we all think that means? Of course we know what that means. That means possibly taking a step back. That means possibly taking a step out. I can share some of my own personal experience. I bled so heavily that I couldn't get up from a chair in a meeting because I didn't want everyone to see that I ruined the chair and my dress. I had rage that was so severe, I couldn't even explain it until it went away, and then I had to explain it away. These were all things that thankfully did not derail my career and had I known that there could have been alternatives or options or treatment, I would have been thrilled to have them. For me, this was years before a menopause moment and people were talking about it. I just did nothing. I had no doctor who even identified it or connected the dots if I raised it. I think in part the answer is we have to know this. Thankfully, the Mayo Clinic did that study that gives us that $1.8 billion and $26.6 billion number so we can throw that around in terms of what the costs to the economy are. We need so much more investigation that way. Research is not just the medical research, but it is these kind of cost benefit analyzes, things that make for talking points and sticky stats that everybody can't help but listen to. Senator Gillibrand. Ms. Weiss-Wolf, did you know anybody who had the same symptoms as you to talk to? Ms. Weiss-Wolf. No. Senator Gillibrand. Because it is not discussed. I just, from this stage, discussed many symptoms that no woman would even want to discuss with her husband, may not even raise with their doctor, certainly isn't going to discuss with their community. Women don't want to discuss these things because there has been a silence to them, to everyone, to not talk about their health. That they are told to suffer in silence. I think the lack of training with OBGYNs generally has amplified that because when they go to talk to their doctor, their doctor might just say, well, I don't know, you can try this. You can try that. I am not sure. Like the lack of interest, the lack of dedication to solving the problem, the lack of knowledge. There is no incentive to talk about it but now that I am 59, I have lived through perimenopause, menopause, now I am post-menopause, I talk to girlfriends all the time. I talk to women all the time. Now I have heard of so many symptoms, I can't believe that I didn't know about any of them before I got to this position in my life and so, that is what this hearing is also about, to just say we must talk about the severity of these symptoms, the outrage that money isn't being spent, the fact that our doctors aren't being trained, and the fact that the American Medical Association doesn't seem to care about what their training is for their doctors. Like, this is all systemic problems, and you guys are all part of the solution. Dr. Lynn Cosslett-Charlton, your turn. Dr. Coslett-Charlton. I would love to address a few of those things. The first, I will go back a little bit, because having this conversation is wonderful and we were talking about social media and the idea that women can feel more empowered by shared stories is wonderful--that they know that there are solutions. Going back to the breast cancer issue and how to treat patients sensitive to breast cancer, I could tell you, not just breast cancer patients, there are other patients where menopausal hormone therapy may not be appropriate for them and for their health and in that patient population, there are a lot of effective treatments. None of them are covered without major cost sharing. There are a lot of problems with access because of that. Second, I spent a lot my time for the last 15 years volunteering in a health clinic in my community for working uninsured women to give them a hand up when they don't have insurance at the time and those patients all suffer menopause. They all suffer the symptoms. Everything that they would do to treat those symptoms is out of pocket and they are not CEOs, and they are not physicians like myself, and a lot of them aren't educated to the same degree that a lot of us are and it isn't just the economic burden for them, but they are worried more about putting food on the table, and working, and being able to, you know, control their symptoms while they are continuing their employment. They are working two, three jobs in my patients at my clinic. Increasing affordable options, investing. You know, fortunately in that clinic there is a lot of private funding. They are really--you know, there is a lot of people that fall through the cracks, and I anticipate, and I am sure you are well aware, next year there is going to be a lot more people falling through the cracks that are uninsured, and a lot of women that are going to need access to affordable options to treat these symptoms so that their lives aren't disrupted. Senator Gillibrand. Last, Dr. Wactawski-Wende. Dr. Wactawski-Wende. Yes. You brought up 10 or 15 different questions. Senator Gillibrand. Pick one. Anyone you like. Your choice. Dr. Wactawski-Wende. What I would like to say is, in 1985, the NIH put forward a study led by Ruth Kirchenstein to look at the issues in women's health and at that point in time, the report said we were not doing enough research on women. That roughly a third of studies even include women. There was very little work in the area of menopause. It was mostly reproductive. We didn't have trainees with enough experience, and we needed to do more to train both clinicians and researchers, encourage women to become researchers because they might be interested in leading those questions. I would argue we are now 35 years later, and we have not come all that far and I do believe that some of what you are purporting here, more research, more education, empowering women with knowledge, and I would say it needs to be rigorous. Evidence based knowledge is what we need, and it is not too early to start, so, thank you for anything you can do to advocate for that for women across the Nation. Senator Gillibrand. Thank you all. Thank you, Mr. Chairman. The Chairman. Well, I want to thank everyone for being here today and participating in this historic hearing. I appreciate Ranking Member Gillibrand's leadership on this issue that affects so many Americans. I look forward to continuing to work with the members on the Committee. If any Senators have additional questions for the witnesses or statements to be added, the hearing record will be open until next Wednesday at 5:00 p.m. Thank you. [Whereupon, at 04:40 p.m., the hearing was adjourned.] ======================================================================= APPENDIX ======================================================================= Prepared Witness Statements ======================================================================= [GRAPHICS NOT AVAILABLE IN TIFF FORMAT] ======================================================================= Questions for the Record ======================================================================= U.S. Senate Special Committee on Aging "Half the Country, Zero Hearings: Meeting the Moment to end the Menopause Care Gap in America" September 16, 2026 Questions for the Record Dr. Jean Wactawski-Wende Ranking Member Kirsten E. Gillibrand Question: Informed by 40 years of research in women's health, including decades as part of the landmark Women's Health Initiative, your testimony highlights the gaps in research for chronic diseases and aging. What types of additional studies are needed? How will this help us develop effective prevention and treatment strategies for chronic diseases influenced by menopause? Response: Women's health research has been understudied for far too long. The 1985 Public Health Service (PHS) Task Force on Women's Health Issues report, chaired by Dr. Ruth Kirschstein, served as a landmark catalyst for changing how we address women's health including clinical research that is specific to women. The report of the Task Force included recommendations on: Promoting a safe and healthful physical and social environment; Providing services for the prevention and treatment of disease; Conducting research and evaluation; Recruiting and training of health care personnel; Educating and informing the public and disseminating research information; and Designing guidance for legislative and regulatory measures. The report revealed that women were routinely excluded from major clinical trials and medical research protocols, and that animals used in baseline studies were predominantly male. The original report can be found at:Https://pmc.ncbi.nlm.nih.gov/ articles/PMC1424718/ #::text=Public%20Health%20Rep,1)%3A73%E2%80%93106. Although this report led to the establishment of the Office for Research on Women's Health in the early 1990's within the NIH and funding for the Women's Health Initiative study, progress more generally has been slow. Adequate research funding specific to women's health remains a key concern. Research studies in women need to include research across the lifespan, but particularly in the years leading into menopause and the post-menopausal time period, when health risks begin to elevate. For example, although we have learned of the risks and benefits of a specific type of hormone therapy in the WHI (conjugated equine estrogen, CEE, alone or with medroxyprogesterone acetate, MPA), newer formulations (including transdermal estradiol with or without micronized progesterone) and at lower doses are now in predominant use in the United States, yet large long-term trials of the risks and benefits of these formulations and doses have not been done. A new clinical trial in early menopausal women to establish the longer-term health risks and benefits of these newer and more frequently used formulations is warranted and could be conducted with sufficient funding. In addition, clinical trials focusing on prevention strategies for conditions that increase as women age (heart disease, cancer, osteoporosis, dementia, frailty) should be supported by federal funding. Prevention strategies not only impact women's lives and can reduce morbidity and mortality, but prevention strategies also save on related health care costs associated with these conditions. We need clinical trials of novel interventions that can reduce risk, and also treat or delay these conditions in women as they age. Such interventions will help women to remain healthier, longer and preferably in their homes, rather than facilities requiring high cost to individuals and societies. Ultimately, prevention strategies will save on health care and caregiving costs. Question: In what ways does instability in federally funded grants impact the ability of researchers like yourself to conduct studies and make scientific breakthroughs? Response: Federal funding through grants and contracts has been the key driver in advancing scientific breakthroughs supporting health in both women and men over time. Federal funding should support research to advance our understanding of the key determinants that maintain health throughout our lifespans and as we age. Many breakthroughs have come as a result of studies funded by the NIH. For example, breast cancer survival is now well-over 90% for most women. Survivorship is a direct result of early detection and targeted treatments identified in studies funded by the NIH. For many cancers and chronic diseases of aging, early detection and targeted treatment interventions is key. Those breakthroughs came from funding from the NIH to extramural scientists. Cardiovascular disease (CVD) is the number one killer of women in the United States, however many women have died prematurely because their symptoms were either not recognized or were misdiagnosed. Symptoms of CVD are different in women and men. NIH funded studies have helped us in understanding early signs of CVD in women and impacted survival, saving lives. NIH-funded clinical trials have supported new regimens to prevent and treat many diseases. We need more funding for key conditions in women. Without federal funding focusing on women, these breakthroughs would not have happened. Continued support is needed. My own PhD work was supported by funding from the National Cancer Institute to study health effects of exposure to ionizing radiation in women. That training allowed me to develop as a scientist and design and conduct studies that have helped to detect and treat diseases in women. NIH funding to support the training of upcoming bright scientists to establish their careers and scientific discoveries serves all of society. Threats to the NIH budget and other federal funding of medical and health research impacts all of us. Recent threats to cut both intramural and extramural research at the NIH and other federal agencies should concern us all. These precious NIH dollars need to be protected and in fact, increased, to support this critical human health research. The United States has been a world-leader in advancing scientific studies to support human health. Any threats to funding should concern all of us. Question: Last April, when the Trump administration indicated its intent to terminate the WHI, what happened? Why was there such a strong response from the community, and what was the result? Response: On April 21, 2025, Women's Health Initiative (WHI) investigators were informed that the Department of Health and Human Services (HHS) would terminate WHI Regional Center (RC) contracts at the end of their current fiscal year, September 2025. I was one of the principal investigators of the Northeast WHI regional center. This notice of cancellation came without warning or explanation. The WHI investigators were shocked, given the remarkable impact WHI had had on women's health. There was a tremendous and immediate pushback from the public, lawmakers, stakeholders, and the media. Women and women's health advocates were very vocal. On April 25, 2025, an HHS spokesperson confirmed to the media that the decision to cancel the contracts had been rescinded. I personally first learned about this reversal from a news media source. WHI investigators received official notice that the WHI would be allowed to continue on May 6, 2025. Our WHI study participants were kept in limbo. At that time point they had been actively participating in the WHI study for 30 years. Prominent researchers, clinicians, and women's health advocates denounced the decision as short-sighted. Women across the United States strongly voiced their concerns. Major celebrities added their voices to the concerns of the public. They warned that defunding the 30-plus-year landmark study would severely disrupt ongoing research on cardiovascular disease, cancer, osteoporosis, dementia and aging in postmenopausal women. WHI was and is the largest and longest study of postmenopausal women of its kind. Given that the WHI was funded as a response to the 1985 report, any chance of de- funding this study was a major step backwards in further understanding of diseases of aging. As a result of this advocacy and public outcry, WHI has continued. The WHI study is currently in its 4th extension period (September 28, 2020, through January 28, 2027). During that period, over 40,000 women continued in the study, 30 years after initial enrollment. The women are now 79-110 years of age. We continue to have over an 80% response rate from these women annually, remarkably 30 years after enrolling. This type of commitment of the study participants is unprecedented. Hundreds of new scientific discoveries are published annually from this rich data source on women's health. Dozens of funded ancillary studies are extending the discoveries from the base WHI study, looking at factors such as sleep, physical activity, diet, mental health, genetics and many of factors on health of women as they age. One current concern is related to funding for the 5th extension study of WHI after January 2028. We are a little over one year from our current funding cycle completion. Yet have not gotten any formal notification on whether the NIH will fund another extension of this landmark study to continue this important work. The WHI investigators continue to submit new ancillary studies to leverage the data and biologic samples available for discovery. Our current focus is on diseases of aging in women 80 and older. As noted above, in April 2025 there was a short period of time when HHS indicated they would discontinue WHI funding. The public outrage was immediate and strong. As a result, funding was quickly restored. The WHI investigators and study participants are waiting eagerly to learn of the future plans to fund the WHI continuation beyond 2028. We would appreciate support from the Senate Special Committee on Aging, especially members interested in research in women after menopause, for continuation of the 5th extension study of WHI. WHI is the most far-reaching study of women after menopause ever conducted. Continued funding of the WHI impacts all women, as these findings will inform our daughters and grandchildren as they age. As background, the WHI participants currently provide updated data annually on their major health outcomes and complete questionnaires on many aspects of their lifestyles, experiences and exposures. The WHI also has information from CMS (Medicare) related to medical services, procedures and medication use through billing records. WHI also maintains a biologic specimen bank of blood samples collected at baseline enrollment, and over time, to explore mechanistic studies underlying medical outcomes and determine biomarkers that can help understand how to detect and prevent disease. Ancillary studies (i.e. add-on studies) have been funded to expand and build onto the WHI database. Examples of currently active ancillary studies include studies of stored blood samples that look at genetic markers of disease, telomere changes with aging, inflammatory biomarkers and much more. WHI women have joined two NIH funded studies of muscle mass (and change in muscle mass over time), in women after cancer treatment and in women with diabetes. Over 5,000 women consented to join these studies and provided study samples of blood and urine that help us to determine changes in muscle mass age we age. Major ancillary studies continue on sleep, physical activity, cognition/dementia, stroke biomarkers, health effects following cancer therapies, the gut and oral microbiome, inflammation and much, much more. Continued NIH funding of WHI is needed to support these discoveries. WHI has a far reach, with participants coming from ALL 50 states in the U.S. Question: Sometimes FDA uses temporary regulatory flexibility to address a drug shortage. If the agency were to consider a supplemental patch supply while U.S. capacity catches up, what assurances would physicians and patients need regarding FDA review, manufacturing quality, inspections, labeling, and ongoing safety monitoring? Response: I cannot comment on the FDA's review process since it is outside of my area of expertise, but I would like to add that ready access to any needed medication should be a priority. Careful oversight of the U.S. drug supply should be a given. On a related point with important relevance, current formulations and doses of hormone therapy treatments on the market have not been studied for their long-term risks and benefits to chronic disease in postmenopausal women in randomized clinical trials. In addition, "compounded" formulations are not carefully regulated. As background, since WHI's hormone therapy trial findings were first released in 2002 and 2004, the types of formulations and the doses of these formulations have changed. Use overall has dropped and many women are now taking transdermal estradiol instead of CEE. Similarly micronized progesterone is more commonly used than MPA. Lower dose options are now available for all these formulations. However clinical trials to study the longer-term risks and benefits have not been conducted to provide women concrete evidence to make their decisions about personal use. It is possible that lower doses and other formulations may have less risky profiles than those studied in the WHI HT trials, however we need to do the necessary randomized clinical trials to be able to estimate the risks and benefits of these newer formulations and doses. I would like to take this opportunity to comment on the July 17, 2025 FDA hearing on hormone replacement therapy. The FDA panel included individuals with perspectives from a variety of disciplines. There were several statements in the testimonies that did not adequately describe the trial finding. Some statements were incorrect. Many statements were not supported by the scientific evidence from randomized clinical trials, including several statements made regarding the Women's Health Initiative (WHI) study results. There were no opportunities during the hearing for public questions or comments. Following the hearing, the WHI Steering Committee drafted a response to the FDA to correct some of the erroneous information that was presented. This response was sent to the FDA for their consideration, but to my knowledge, the WHI Steering Committee has not received a response to that letter from the FDA. Below is a copy of that statement which corrects or adds context to the information presented to the FDA by panelists. This is important information that should be carefully considered by the FDA and the Menopause and Aging panel. Some comments made by witnesses at the September 16, 2026 Senate Special Committee on Aging panel repeated some of the erroneous information from the FDA panel. Women need the most accurate information, and I am including below the content of the letter sent to the FDA panel by the WHI Steering Committee for consideration here. See the WHI response below, shaded in light gray : Women's Health Initiative Comments on FDA Panel on Menopause and Hormone Replacement Therapy for Women (Docket: FDA: 2025-2589) For over 30 years, the Women's Health Initiative (WHI) has conducted groundbreaking research on the health of postmenopausal women. Prior to WHI, women were often excluded from health and medical research, and many pharmaceuticals were prescribed for women without rigorous testing for safety or efficacy. We are pleased to see renewed interest in the health of postmenopausal women, and we urge that any new medical recommendations for this age group be based on rigorous science. During the FDA Expert Panel on Menopausal and Hormone Replacement Therapy for Women on July 17, 2025, the results of the WHI randomized controlled clinical trials of menopausal hormone therapy (MHT) were repeatedly cited in the panelists' presentations. In some instances, the WHI findings and their interpretation were presented accurately, but in other instances panelists' statements and the presentations were inaccurate, misleading, or out of context. Additionally, some panelists emphasized favorable findings while omitting context, creating a partial view of the evidence, particularly for combined estrogen plus progestin (CEE+MPA). To inform evidence- based health care decisions for the nation's women, and in the interests of public safety, the FDA needs to make recommendations for health care based on the best available data, for which the gold standard is the peer reviewed summaries of the randomized controlled clinical trials. The FDA should not make decisions based on anecdote or misinformation presented by persons with known bias or conflicts of interest. As representatives of WHI, we herewith provide a summary of the WHI peer reviewed trial design and results, together with a historical context and commentary where indicated. Why were the WHI trials necessary? Premarin (conjugated equine estrogens) started being used in the 1940's for the relief of menopausal symptoms. To counter a multifold increased risk of endometrial cancer in women who had not had a hysterectomy a progestogen (medroxyprogesterone acetate) was added in the late 1970's. By the 1980's and 1990's MHT was increasingly being used for very different reasons: prevention of osteoporosis and cardiovascular disease. Though the potential risk for breast cancer was recognized, the benefit for prevention of coronary heart disease (heart attacks) was thought to outweigh the risks of MHT. Whereas earlier use of these hormones for treatment of menopausal symptoms was primarily in younger women (who were the most likely group to have vasomotor symptoms), the later use for prevention of osteoporosis and cardiovascular disease shifted the age spectrum towards older women (who were most likely to have these conditions). According to National Health and Nutrition Examination Survey (NHANES) data in 2001-2002 overall prevalence of hormone use was 29.5%, with 26.2% prevalence in women aged <52, 38.5% at age 52-<65, and 23.2% at age >65 years.1 Use of hormones for prevention of heart attacks at all ages and including women with existing heart disease was encouraged by medical society guidelines. The enthusiasm for hormones for heart attack prevention was driven by promising findings from non-randomized observational studies in women free of heart disease as well as in women with existing heart disease. These studies predominantly involved use of conjugated estrogens alone but also studied use of CEE+MPA compared to non-users. Observational studies could be biased towards benefit for many reasons, including that women using MHT were generally younger, healthier and more likely to engage in favorable health behaviors than nonusers, leading to confounding by indication and lifestyle. However, that is not the entire explanation, since MHT also appeared to protect against second heart attacks in women with existing disease. Hence, there was a need for large randomized controlled trials to settle the issue of prevention of chronic disease in both primary prevention in healthy women, and secondary prevention in women with existing heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS) of CEE+MPA tested whether promising observational studies in women with existing heart disease would hold up in a rigorous clinical trial, and similarly the WHI trials tested whether observational studies suggesting benefit in generally healthy women would hold up. WHI tested conjugated equine estrogens (CEE-alone, in women with a hysterectomy) and CEE+MPA (in women with an intact uterus) (the trials are also known as E-alone and E+P trials).2-4 Both placebo-controlled trials studied the drugs and doses that promised benefit based on observational data, and which were the drugs most prescribed at the time. The enrollment age range in the WHI trials was 50-79 years so that informative data could be generated for both younger and older women and to ensure statistical power for the primary outcome of coronary heart disease (heart attacks). The WHI trials were not designed to test the effects of hormones on vasomotor symptoms, a well-established benefit, but contrary to a common misconception, women with vasomotor symptoms were enrolled if they passed a 1-month placebo run-in period; women currently on hormones could be enrolled if in addition they passed a 3-month washout period. WHI plans to publish a report specifically addressing the trial health outcomes in women with vasomotor symptoms (Rossouw et al, in press). WHI randomized 8833 women aged 50-59 years in the MHT trials, and one quarter of them, reported moderate-severe vasomotor symptoms at baseline, with smaller percentages at older ages. the WHI was and still is the largest study of MHT in this age-group and hence, much of the high-quality data cited by the panel about health outcomes on MHT in younger women is derived from the WHI trials. What did the trials show? HERS results were announced in 1998 followed by the results of the WHI trial of CEE+MPA stopped early in 2002 (after mean follow-up 5.2 years) following a recommendation from the trials' Data Safety and Monitoring Board. Both trials showed no benefit for prevention of heart attacks and an increased risk of blood clots, with significantly higher risks for both heart attacks and blood clots in the first 2 years.2,3 The WHI CEE+MPA trial also showed an increased risk of stroke and breast cancer, and a benefit for fractures and colorectal cancer. In 2004, the WHI trial of CEE-alone was also stopped early following a decision by the NIH and results published (after mean follow-up 6.8 years); these showed an increased risk of stroke, reduced risk of fractures, and non-significant trends towards reduced risk of heart attacks and breast cancer.4 Thus, the trials achieved their primary aim of clarifying that menopausal hormone therapy did not significantly reduce risk of heart attack. Importantly, the risk-benefit profile of E-alone was better than that of E+P. Note that the primary results were based on incomplete follow-up at the time of early stopping, and that complete treatment period follow up of 5.6 years in the CEE+MPA trial showed some subtle but important changes, in that the increased risk for heart attacks was no longer statistically significant, but the increased risk for breast cancer became significant. CEE-alone trial results after full follow up of 7.2 years did not differ from those of the primary papers.6 What was the impact of the trials? WHI investigators have recently published a comprehensive review of trial results and their clinical implications.7 Following publication of the WHI CEE+MPA trial results, practice guidelines no longer recommended MHT for prevention of heart disease, and the FDA applied a black box warning to all MHT products. There was a marked reduction in the use of MHT for disease prevention in older women but even though use of hormones for menopause symptom management was not part of the aims of WHI, the findings led to a marked reduction in use of both combined E+P and E-alone for relief of vasomotor symptoms in younger women and a reduction in training for menopause management at medical schools. According the NHANES data, in 2017-2020 prevalence of hormone use was down to 4.7% overall, with 9.4% prevalence in women aged <52, 4.5% in women aged 52-<65, and 4.3% in women aged >65 years.1 From the outset WHI investigators have recognized that use of MHT for treatment of vasomotor symptoms in younger women is a reasonable option despite the findings for major health outcomes. As early as during the 2002 announcement of the WHI trial results, the National Institutes of Health (NIH) included in the press release a statement from Dr. Jacques Rossouw, Acting Director of the WHI that "Women with a uterus who are currently taking estrogen plus progestin should have a serious talk with their doctor to see if they should continue it. If they are taking this hormone combination for short-term relief of symptoms, it may be reasonable to continue since the benefits are likely to outweigh the risks. Longer term use or use for disease prevention must be re-evaluated given the multiple adverse effects noted in WHI." https:// www.sciencedaily.com/releases/2002/07/020710081413.htm. Dr. Rossouw also stressed the small absolute risks in individual women, though noting that on a population basis the effects could be large. Since the WHI trials were stopped in 2002 and 2004, WHI investigators have published a series of papers to clarify risks and benefits by age group and by years since menopause. These analyses collected and adjudicated health events linked to the intervention for the full treatment period of 5.6 years in the CEE+MPA trial and 7.2 years in the CEE- alone trials, providing more outcomes and follow-up during the treatment period than the initial trials' reports. In addition, cumulative long-term (intervention plus post-intervention) follow-up results describing over 2 decades of information-- particularly relevant for cancer outcomes-have been published. The papers confirm that although the relative risks CEE+MPA or coronary heart disease (heart attacks) did not differ significantly by age, the absolute risks are small in women under age 60, while absolute risks are high in women over age 70, and especially so in older women with persistent vasomotor symptoms.5-8 In addition, the influence of MHT on cardiovascular outcomes quickly diminished and was not evident during postintervention phase, while the influence on breast cancer persisted (breast cancer remained significantly increased in the CEE+MPA trial, and the previously non- significant reduction in the CEE-alone trial became significant). What is the current status of hormone therapy? Over the years since release of the WHI findings the Menopause Society and others have continued to emphasize that hormone therapy is the mainstay of treatment for vasomotor symptoms, and that absolute risks of such therapy are low in younger women; however, NHANES data indicate that as of 2020 the uptake of hormone therapy in younger women has not increased during the last 2 decades.1 Oral estrogens are now prescribed less frequently than transdermal and intravaginal routes, and among oral products CEE and CEE+MPA are less frequently prescribed than estradiol and progesterone. Unlike the MHT pharmaceuticals tested in WHI, use of other oral MHT pharmaceuticals is not supported by the same high-quality data on health effects. Issues raised by panel members: Timing hypothesis for coronary heart disease and total mortality: Several speakers assumed that the timing hypothesis was valid, i.e., that hormones started at an early age would have lower risks and that the lower risk would carry over into subsequent decades. The first part is supported by WHI data from the 8,833 women aged 50-59 years enrolled in the trials, at least insofar that they have lower absolute risks than older women.5-8 The second part, however, remains untested and cannot be proven from WHI clinical trial data or observational studies; it reflects hope rather than solid scientific evidence. The WHI trial data describe initiation of relatively short-term (5-7 years) MHT use; it is not feasible to obtain longer term trial data capturing initiation at younger ages and continued into older ages. Traditional observational studies of hormone users can do this, but such studies are not well suited to address long term effects because they are prone to several biases and confounders that skew results in a favorable direction; some of these biases can be overcome with newer methods of analysis, which then provide estimates similar to those of the trials.9,10 More specifically, in these newer analyses the trial and observational data align in showing an increased risk of heart attacks in the first 2 years, and then an attenuation or a reversal to benefit in later years. In addition to any differences by age or time since menopause at the time of initiation, the apparently more favorable overall results in the observational studies are due in large part to their longer duration, when the initially increased heart attack risks in susceptible women are countered by reduced risk in surviving women. Long term observational studies have other issues, since women who continue hormones for decades are very different from non-users in terms of general medical status and health behaviors. A very long term very large randomized controlled trial in younger women with perfect adherence would be needed to answer this question, but such a trial is not feasible. Thus, the question of whether initiation at a younger age and continued into older ages will result in benefit or harm as women and their arteries age remains open. What we do know is that risks increase when hormones are initiated at older ages, especially so in those with persistent vasomotor symptoms.5,6 The panel was shown data from the trials in the age group 50-59 years which show low absolute risks or benefits for a number of trial outcomes. The data shown are correct, but somewhat misleading. For most health outcomes there was no statistical evidence that the MHT relative risks differed by age groups. In addition, the materials presented large absolute reductions for all fractures and diabetes, but not the large absolute increases in gallbladder disease and urinary incontinence.6, 11-12 We encourage the FDA to review Manson et al. (2013; 2017; 2024) for the influence of MHT across a comprehensive range of outcomes, for the full cohort, as well as stratified by age group, and to consider the formal statistical tests for age-related trends.6-8 The WHI trial data support short-term use of hormones at younger ages because of their low absolute risks, and that is sufficient reason to allow for short-term use for their traditional indication--relief of vasomotor symptoms. On the other hand, WHI does not provide information on long term use for heart disease or mortality prevention. Instead, WHI data reflect the effects of MHT taken during the 5-7 years of the intervention, with prolonged non-intervention follow-up, rather than prolonged use. Since initiation of hormones at older ages is associated with increased risks, they should not be used to prevent heart disease or mortality. The panel was informed about a Finnish observational study showing that discontinuation of hormone therapy was associated with higher risks of cardiac and stroke deaths compared to population controls or to women who continued therapy.13 It is unclear why this observational study was referenced when we have data from a randomized placebo-controlled trial where hormones and placebo were simultaneously stopped programmatically at the end of the treatment, as opposed to unknown reasons why women elected to start and stop in the Finnish study. In the WHI trials, the increased risk of cardiovascular events was seen during the intervention and rapidly diminished during the postintervention. In addition, the relative risks for cardiac and stroke mortality were neutral during 18 years of follow-up (including 11 years of post-trial follow-up).8 In the CEE+MPA trial the risk of heart attacks decreased after stopping, and in both the CEE-alone and CEE+MPA trials risks of strokes and blood clots decreased after stopping.6,7 Thus, the trial findings are not only diametrically opposed to those of this particular observational study but also indirectly support the causal role of hormones during the trial. It would be ironic if observational data were now used to counter the very trial evidence designed to address the limitations of earlier observational studies. We encourage the FDA to review Manson et al. (2013; 2017) for the cumulative influence of MHT across a comprehensive range of outcomes, and Heiss et al. (2008) and LaCroix et al. (2011) for detailed analyses of shorter-term postintervention follow-up.6-7,14-15 The panel was told that 50,000 women died over 10 years because they were denied estrogen at age 50-59 after publication of the WHI findings.16 Their estimate was based on the difference in absolute mortality rates for women aged 50-59 years15 and declines in hormone use after the publication, but selectively ignores that the estimated reduction in mortality during the trial was not statistically significant, as well as results of women aged 60-79 that were also randomized in the WHI trial.15 We encourage the FDA to review the original results reported by LaCroix et al,15 methods used by Sarrel et al,61 and WHI's published reply.17 Nonetheless, we agree that younger women have lower relative risks of mortality than older women,7-8 and that the low absolute risks in younger women, particularly in the E-alone trial, do allow for the safe use of hormones to treat vasomotor symptoms. Timing hypothesis for cognitive function and dementia: The panel was shown observational data to support that hormone therapy and longer duration of hormone therapy is associated with lower risk of neurodegenerative diseases including Alzheimer's, supported by rather elegant metabolic studies of brain glucose and ketone metabolism, inflammation, and loss of white matter across the menopause transition. The hypothesis is that the effect of hormones on the brain is dependent on whether they are initiated at the peri-menopausal, immediately menopausal, or post-menopausal time with benefit at earlier periods and harm later. While attractive, the framework is partially informed by observational studies which we know to be biased due to predominant enrollment of generally healthier people (e.g., fewer people who smoke, more people who engage in recreational physical activity and have healthy weights). Short-term trials of MHT for cognition have given mixed results. We do not have long term trials of MHT for dementia prevention started in early menopause, but in the WHI trial of women aged 50-54 studied 7 years after trial ended there was no residual benefit for MHT regarding cognition. In women aged 65 and older, there was harm for probable dementia/mild cognitive impairment during the trials.8 We encourage the FDA to review WHI's MHT trial results on cognitive function among younger women by Espeland et al, and probable dementia by Shumaker et al.18-19 Breast and other cancers: While the cancer data shown were correct, the presentations and discussions were potentially misleading. Most importantly, it has been repeatedly mentioned that the 2002 CEE+MPA paper only "suggested" an increase in breast cancer incidence and that there was no significant increase in breast cancer mortality. This statement distorts the appropriate statistical inference and ignores the totality of the evidence that has been presented over time. The CEE+MPA trial was stopped early, on the advice of the independent data and safety monitoring board (DSMB), when the protocol-specified breast cancer statistic (weighted logrank Z=-3.19, 2p=.001) crossed the prespecified monitoring boundary for harm (Z=-2.32, 2p=0.01) at mean follow-up time of 5.2 years.3 This adverse effect emerged approximately 10 years earlier than the protocol projected time at which adequate power to detect breast cancer harm would be achieved.3 Using trial data through the end of blinded intervention (5.6 years), the risk of incident invasive breast cancer was significantly increased (HR 1.24, weighted logrank P<.001 ), although the confidence interval based on a simplified analysis included 1.0 (ref: PubMed #12824205). An increased risk in breast cancer was evident across all age groups, including younger participants randomized to CEE+MPA (< 60 y; HR 1.36; 95%CI 1.09 - 1.69)23 and no statistically significant variation by age group in breast cancer outcomes has been seen. These increased risks have persisted throughout the post-intervention period; published updates reported a 28% increase at 13 years and the 28% increase at 20 years of cumulative follow-up.6,23 Additional analyses support a causal interpretation. Analyses examining risk by time in study and adherence to study pills found that breast cancer risk increased for women in the CEE+MPA group with both of these measures of increasing exposure to study hormones (Chlebowski, 2009). In another analysis that considered duration of exposure, those with hormone exposure prior to the trial were at higher risk, whereas those without prior use showed no elevation during the active intervention period25. The distinction by prior hormone use was no longer significant in the 20-year update, as breast cancer incidence was significantly elevated with CEE+MPA in both those with prior MHT use (HR 1.52; 95%CI 1.16-1.98) and those without prior use (HR 1.21; 95%CI 1.05-1.40), directly refuting claims that the overall WHI conclusion rests on an "anomalous" placebo rate.23 The statement about no significance for mortality is similarly problematic. It is dismissive of real injury to women with breast cancer who must undergo arduous therapies including chemotherapy, radiation and surgery, with lasting physical and emotional consequences, as well as significantly increased all- cause mortality.23 It also does not acknowledge the fact that tumors in the CEE+MPA group were larger, later stage, and more likely to involve lymph nodes than those in the placebo group-- findings inconsistent with chance variation, but consistent with delayed detection due to increased breast density attributable to CEE+MPA.24 Further, while no increase in breast cancer mortality was observed at the time the trial was stopped, likely because of few deaths observed at that point, longer term follow-up found a 96% increase in deaths attributed to breast cancer at 11 years mean follow-up (p=0.049) (REF: Chlebowski, JAMA 2010). During the panel discussion, a speaker claimed that the decline in U.S. breast cancer incidence that followed the stopping of the WHI CEE+MPA trial was "a statistical change in how the data was being analyzed by the group from the CDC." The speaker's claim is unsubstantiated and not consistent with SEER coding. The report by Ravdin et al. (2007) attributed the sharp decline in U.S. breast cancer incidence after 2002 primarily to the abrupt reduction in postmenopausal hormone therapy use, particularly combined estrogen plus progestin, following the early termination of the WHI CEE+MPA trial.27 The analysis was peer-reviewed and published in one of the most rigorous medical journals. There are no known technical flaws in the methodology, NEJM has never retracted, corrected, or revised these findings. We encourage the FDA to fully examine the U.S. breast cancer incidence following the stopping of the WHI trial, and temporal trends reported by Chlebowski et al. (2015; 2020).23,28 As accurately noted by one speaker, CEE-alone showed a nonsignificant reduction in risk for breast cancer (at 7.1 years). This reduction persisted and became statistically significant in longer term follow-up. Breast cancer mortality was also reduced after 20 years.24,26 We encourage the FDA to fully examine the influence of MHT and particularly CEE+MPA on breast cancer incidence, tumor characteristics, mammography rates, and breast density, as well as the long-term follow-up.22,24 Other Cancers: The speaker's statements regarding WHI portrayal of MHT's association with lung cancer and ovarian cancer are inaccurate, as evident in our trial reports.20-22 The panel was told that neither WHI trial showed an increased risk of lung cancer among 50-59 year old women. While technically accurate, it is misleading to focus on a specific age-group without considering the larger picture. There was no statistically significant age trend in either trial so conclusions should be based on the entire dataset. CEE+MPA significantly increased risk of lung cancer deaths, but not incidence20 whereas CEE-alone did not significantly increase either lung cancer incidence or death.21 The evidence for WHI's MHT trials on lung cancer should be interpreted cautiously, however, as this outcome was not a designated endpoint. CEE-alone significantly increased risk of ovarian cancer incidence by 104% and risk of dying from ovarian cancer by 179%, while CEE+MPA did not.22 Again, the lack of significant interactions by age indicates that the most reliable inference is based on the overall results. Conclusions The WHI trials were primarily designed to study whether MHT would reduce heart attacks across all ages spanning 50-79 years. Additional outcomes that might be affected by MHT were studied, including breast cancer as the primary safety endpoint. The trials achieved their primary objectives. Results showed that MHT did not reduce the risk of heart attacks but increased the risk of stroke and blood clots. Breast cancer risk was increased, and endometrial cancer decreased in the CEE+MPA trial. Fractures were reduced in both trials. The WHI trials were not designed to study the effects of MHT specifically in younger menopausal women with vasomotor symptoms (the main current indication for MHT); nonetheless the 8,833 women aged 50-59 years represent the largest MHT trial in this age group. In this younger age group, the relative risks were like those of older age groups in the CEE+MPA trial, whereas in the CEE-alone trial women aged 50-59 years had significantly lower risks for heart attack, and all-cause mortality compared with older age groups. The important take- home messages from the results in the younger age groups are that CEE-alone has a more favorable risk profile, and that in both trials the absolute risks were low. The low absolute risk in younger women is a sufficient rationale to justify short term use of MHT for relief of vasomotor symptoms. The panel discussion raised the issue of the black box warning on MHT products, particularly topical vaginal products. The WHI investigators do not take a position on whether the FDA should remove or modify the black box warning on MHT products. We recognize that the FDA's boxed warning for all estrogen products was rooted in the WHI systemic (oral) hormone trials conducted to test chronic disease prevention in women aged 50- 79. However, those randomized trial results do not evaluate and may not apply to vaginal estrogen used locally for the genitourinary syndrome of menopause or to transdermal MHT for vasomotor symptom relief. We encourage the FDA to reevaluate whether extrapolating systemic WHI findings to local products is appropriate. In summary, WHI has contributed enormously valuable knowledge to help women make health care decisions. It is unknown whether other systemic MHT products such as estradiol or progesterone will have similar effects to the conjugated equine estrogens and medroxyprogesterone used in the WHI trials, because of a lack of similarly large and rigorous trials in healthy women. The WHI data remain the best data available to inform health care recommendations with regard to systemic MHT. The Women's Health Initiative Steering Committee/ www.whi.org References: 1.Yang L, Toriola AT. Menopausal hormone therapy use among postmenopausal women. JAMA Health Forum. 2024;5(9):e243128.14. 2.Hulley S, Grady D, Bush T, et al. Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. JAMA. 1998;280(7):605- 613. doi:10.1001/jama.280.7.605 3.Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. 4.Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004; 291(14):1701-1712. 5.Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause. JAMA. 2007;297(13):1465-1477. 6.Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Post Stopping Phases of the Women's Health Initiative Randomized Trials. JAMA. 2013;310(13):1353-1368. 7.Manson, JE, Crandall CJ, Rossouw JE, et al. The Women's Health Initiative randomized trials and clinical practice: A review. JAMA; 2024;331(20):1748-1760. 8.Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: The Women's Health Initiative randomized trials. JAMA 2017;318(10):927-938. 9.Hern n MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766-79. 10.Rossouw JE. Reconciling the divergent findings from clinical trials and observational studies of menopausal hormone therapy for prevention of coronary heart disease. Semin Reprod Med. 2014;32(6):426-432. 11.Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of Estrogen Therapy on Gallbladder Disease. JAMA. 2005;293(3):330- 339. 12.Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of Estrogen With and Without Progestin on Urinary Incontinence. JAMA. 2005;293(8):935-948. 13.Venetkoski M, Savolainen-Peltonen H, Rahkola-Soisalo P, et al. Increased cardiac and stroke death risk in the first year after discontinuation of postmenopausal hormone therapy. Menopause 2018;25(4):375-379. 14.Heiss G, Wallace R, Anderson GL, et al. Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin. JAMA. 2008;299(9):1036-1045. 15.LaCroix AZ, Chlebowski RT, Manson JE, et al. Health Outcomes After Stopping Conjugated Equine Estrogens Among Postmenopausal Women With Prior Hysterectomy: A Randomized Controlled Trial. JAMA. 2011;305(013):1305-1314. 16.Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years. Am J Public Health. 2013;103(9):1583-8. 17.Prentice, R.L., Manson, J.E., Anderson, G.L., LaCroix, A.Z., Shumaker, S.A., Chlebowski, R.T., Howard, B.V., Stefanick, M.L., Jackson, R.D., Wactawski-Wende, J. and Rossouw, J.E., 2013. Women's Health Initiative View of Estrogen Avoidance and All-Cause Mortality. American Journal of Public Health, 103(12), pp.e2-e2 18.Espeland MA, Shumaker SA, Leng I, et al; WHIMSY Study Group. Long-term effects on cognitive function of postmenopausal hormone therapy prescribed to women aged 50 to 55 years. JAMA Intern Med. 2013;173(15):1429-1436 19.Shumaker, Sally A., et al. "Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study." JAMA 291.24 (2004): 2947-2958. 20.Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. The Lancet 2009, Volume 374 (9697), 1243 - 1251. 21.Chlebowski RT, Anderson GL, Manson JE, et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst. 2010 Sep 22;102(18):1413-21. 22.Chlebowski RT, Aragaki AK, Pan K, et al. Menopausal hormone therapy and ovarian and endometrial cancers: Long-term follow- up of the Women's Health Initiative randomized trials. Journal of Clinical Oncology. 2024; 42 (30) suppl https://doi.org/ 10.1200/JCO.2024.42.16--suppl.10506 23.Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. JAMA. 2020;324(4):369- 380. 24.Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial. JAMA. 2003;289(24):3243-3253 25.Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas. 2006 Sep 20;55(2):103-15. 26.Stefanick ML, Anderson GL, Margolis KL, et al. Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy. JAMA. 2006;295(14):1647-1657. 27.Ravdin, Peter M., et al. "The decrease in breast-cancer incidence in 2003 in the United States." New England Journal of Medicine 356.16 (2007): 1670-1674. 28.Chlebowski RT, Rohan TE, Manson JE, Aragaki AK, Kaunitz A, Stefanick ML, Simon MS, Johnson KC, Wactawski-Wende J, O'Sullivan MJ, Adams-Campbell LL, Nassir R, Lessin LS, Prentice RL. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials. JAMA Oncol. 2015 Jun;1(3):296-305. Question: I am pushing to pass the bipartisan Advancing Menopause Care and Mid-Life Women's Health Act, led by Senators Murray and Murkowski. The bill would make a historic investment of $275 million dollars into critical biomedical, public health, clinical, and translational research through NIH. For far too long, mid-life women's health has suffered from underinvestment and systemic oversight; this bill provides dedicated resources to transform the standard of care. In what ways would delivering $275 million in grants over five years transform the landscape of research for mid-life women, and how might this impact aging women's health outcomes? Response: In 1985, the NIH put forward a study led by Dr. Ruth Kirchenstein to look at research funding for women's health. That task force identified that women were sorely under- represented in major research studies funded by both the NIH and private industry. Although some movement was made to include women in clinical research, I would argue that 35 years later we have not come that far. There is a need for more research funding to support research in women at all ages, but particularly for the menopausal and post-menopausal time frames. The bill proposed by Senators Murray and Murkowski would provide funds specific to study these critical issues in women's health. I fully support and applaud this Bill and hope more initiatives like these will be forthcoming. The funds that are proposed would be transformative. Question: We've heard from each of you about how additional research would drive advances in provider training, public education, and novel treatments. What do you view as the most pressing gap in menopause research? Response: We are an aging society. The demographics are shifting in the U.S. with the number of women over age 50 nearly doubling in the next two decades. We are unprepared to manage the needs of this growing part of our country. Investing in studies that can inform women on how to stay healthier, longer are key to managing this growth in our aging society. Prevention is key. Early detection is key. Promoting resilience is key. As we establish additional evidence, we need to train our health professionals on the evidence to help them discuss this information with their patients. Additional training on menopause and associated health concerns needs to be emphasized in the training of physicians and other health professionals. Last, dissemination from trusted sources directly to women is also a key area the federal government invests in and should be maintained. Senator Raphael Warnock Question: The Women's Health Initiative is the largest national health study focused on the prevention of heart disease, breast and colorectal cancer, and osteoporosis in postmenopausal women. Since its establishment in 1992 by the National Institutes of Health (NIH), WIH has led groundbreaking discoveries about menopause and the impact on mid-life women's health conditions. Despite its importance, the Trump administration attempted to terminate more than four regional WHI centers in April 2025. It also recently proposed an executive order to grant more decision-making authority to political appointees in the NIH grantmaking process, allowing the administration to further censor menopause research by categorizing it as "diversity, equity, and inclusion." How does menopause affect the heart health of middle-aged women? Response: Thank you for these important questions. In my earlier response I addressed the temporary funding pause for WHI. I also have indicated that we do not know whether WHI will be funded for a 5th extension study beyond January 2028. Support of WHI by our elected officials and this committee on aging would be appreciated. You also mentioned a proposed a second question related to an executive order, that if implemented, would grant more decision-making authority to political appointees in the NIH grantmaking process, allowing the administration to further censor menopause research by categorizing it as "diversity, equity, and inclusion." Historically, NIH funding has been determined though a peer-review process, where teams of expert scientists in various fields review and score proposals on their significance, innovation, methodology, investigator team and the research environment of their institutions. This peer review process has led to support of the most highly regarded science in the world. Historically, those peer reviews were then considered by scientists within the NIH, and also considered in light of the priorities of the agency, and funding decisions were made. Having political appointees who may have no scientific backgrounds and who are not informed on the state of the science, could lead to selection of research that is not making the best use of those precious resources. It may also lead to politicizing science funding based on beliefs that may not be for the greatest societal good. The peer review system has led to great discoveries over many decades. It is my belief that maintaining this peer review system will ultimately lead to the best investments in science to advance health in our communities. Leave the decisions on funding to those who know it best. Last, you inquire about heart health. Cardiovascular disease is the number one killer of women in the United States. As women age, heart disease increases. As we age, more women than men die of heart related conditions in the United States. It appears that the increases in heart disease in women begin to emerge after the ages at which women reach menopause. One belief is that higher estrogen levels in women at younger ages prior to menopause may be a protecting factor. That may be true. However, many changes occur as women age that also may contribute to increasing heart disease (reduced physical activity; co-morbidities such as diabetes and hypertension; increased inflammation). We need to understand all of these factors at more in-depth levels. We can only do that with funding to conduct additional studies to better understand heart disease (and other conditions) in women as they age. Question: How many menopause-related NIH grants were terminated since the beginning of the Trump administration in January 2025? Response: I do not know the number of menopause related grants that were terminated since the current administration began. I have reported that the WHI was terminated for a short period of time in April 2025. I have also reported that we remain uncertain if future funding will be made available to continue that valuable study after January 2028. Any support for continuation of funding for the WHI would be appreciated. As a dean of the University at Buffalo School of Public Health and Health Professions, I am aware that funding for critical training grants to support graduate education in public health have been cut substantially. We had a training grant that is no longer supported by the current administration. It would be helpful to understand the extent of funding changes that have impacted research funding in women's health and also in training grants. I do think that a report on grant funding terminations should be done. Also looking at funding investments that include women and minority human subjects over the past five years would be helpful to see. That data should be available for every funding cycle. Question: How would the Trump administration's recent proposal to establish a new executive committee reviewing NIH grants affect the future of WHI and menopause research at large? Response: It is not clear what the purpose of such a new executive committee would be. The historical use of peer review system has generally worked to help the scientific community weigh in on the best science. I am not sure that appointees with limited depth of knowledge of science and research priorities are best suited to make these decisions. More clarity on the role of peer review in these proposed changes is needed. I would like to note that over the past nearly 2 years, there have been many delays in grant reviews and decisions on funding that have been very disruptive to the research community. These delays have resulted in inefficiencies, with investigators needing to re-submit proposals to avoid gaps in funding. It also has put a burden on the peer review system, because of the lack of timely notifications. In the past 2 years study sections have been postponed, council review dates have been delayed, and those actions have led to delays in funding award notices. We need to get this process back on track. Question: What can Congress do to address the gap in medical research on the prevention of menopause-related health conditions? Response: Congress can help address the gaps in medical research on the prevention of menopause related conditions by first, supporting maintaining or increasing the NIH budget. Supporting additional funding by the NIH that focuses on menopause and women's health research is key to addressing gaps in our knowledge. The proposed bill from Senators Murry and Murkowski. "Advancing Menopause Care and Mid-Life Women's Health Act", is a very good start to address this issue. There is need to also support specific clinical trials to establish risks and benefits of certain therapies in women. Although we can learn a tremendous amount from observational studies, clinical trials are the gold standard of evidence and trials should be demanded in instances where we are making clinical recommendations, especially related to medications and other interventions with potential for risk. Of course, this all requires steady and stable funding. It also requires maintaining operational practices at the NIH to support these advancements. Much more investment into the NIH and other similar agencies should be a priority. Support of the proposed bill is an essential first step. Thank you for the opportunity to respond to these questions. Thank you for your leadership focusing on the health of women as they (we) age. U.S. Senate Special Committee on Aging "Half the Country, Zero Hearings: Meeting the Moment to end the Menopause Care Gap in America" September 16, 2026 Questions for the Record Dr. Lynne M. Coslett-Charlton Ranking Member Kirsten E. Gillibrand Question: Despite limited federal investment in menopause and mid- life women's health research, we've made great advancements in treating symptoms of menopause, particularly with hormone therapy. However, many women still cannot access the care they need. From your perspective as a clinician, what are the most significant barriers impacting women's ability to access treatment? How does that change based on where they live? Response: From my perspective as a physician, one of the biggest barriers is simply finding an ob-gyn in their community. Physician shortages are a real problem, including in the community where I practice, and I urge Congress to act on this complex and growing challenge. Cost and insurance coverage are another major barrier. Treatment options exist, but women may face out-of-pocket costs, inconsistent insurance coverage, or prior authorization and step therapy protocols that stand in the way of receiving treatment. In addition, until very recently there was a black box warning on both low-dose and systemic estrogen, meaning that at times, even if a woman was prescribed HRT, the warmings on the label discouraged her from taking it. Question: What can Congress do to help address some of these barriers, like OB-GYN shortages, estrogen patch shortages, and insurance coverage disparities? Response: Increased investment in the physician workforce and addressing the maldistribution of ob-gyns will enable the United States to better meet the growing need for menopause care. To recruit more physicians to communities with fewer ob- gyns, we need to make sure the system supports and values the care they provide. Current payment structures make it challenging for facilities and small private practices to operate in rural areas. We also need to address the cost and burden of medical liability, which can be a significant barrier to practicing obstetrics. Finally, Congress must also invest in residency training programs and financial incentives for residents to train in rural areas, as data shows that most doctors remain in the areas where they train. National Health Service Corps is a great example. In my office, every day we have a nurse fielding a lot of questions from patients looking for patches. The shortage has become cumbersome and burdensome as they look to access the medication. We have also seen an influx of prior authorization requests for the estrogen patch, which further slows down access. While there are alternative treatment options to the patch, they may not be as affordable. This means that patients experience gaps in treatment and wind up in an on again/off again cycle with their symptoms. Congress should urge the FDA to expediently investigate and address the shortages of estradiol products. Generally, inconsistent insurance coverage remains a significant barrier to accessing care. Varying by payer, treatments may be subject to prior authorization, step therapy or clinical criteria. Congress should expand insurance coverage for menopause treatment, which can help ensure more equitable access to affordable care for patients. Maintaining Medicaid coverage and adequate reimbursement is also essential to ensuring that women have somewhere to go for care. Medicaid cuts have a direct impact on whether women can get the care they need. When coverage is reduced or lost, women may delay or forgo care altogether-not because they don't need it, but because they cannot afford it. The result is that women suffer needlessly, and conditions that could have been addressed earlier can become more serious and more costly to treat. Question: In what ways does peer-to-peer education play an essential role in training OB-GYNs? Response: A significant amount of learning happens after medical school-as you see patients, collaborate with your peers and mentors, and as a practicing physician, you continue to learn. As new science emerges and clinical guidance evolves, continuing education plays an important role in ensuring we are providing the highest quality, most up-to-date care. I often turn to my colleagues, as well as ACOG and other organizations that have a number of resources to help clinicians feel well- equipped and confident to provide this care through every phase of their career. Question: How do ACOG and other organizations contribute to evolving continuing medical education, and where would additional federal support or coordination be most helpful in accelerating that work? Response: ACOG provides clinical guidance and resources for physicians, including continuing medical education opportunities such as menopause certificates, and educational tracks dedicated to menopause care. ACOG also provides free patient-facing web-based resources and a book to help patients navigate this transition. Congress can play a role in improving public awareness and supporting education on menopause. Question: In your practice, to what extent does a patient's coverage policy dictate their ability to access the treatments they need? Response: Coverage and affordability remain among the most significant barriers to menopause care. Even when effective treatments exist, patients cannot benefit from them if those treatments are unaffordable or difficult to access. Depending on the payer, patients may encounter prior authorization requirements, step therapy protocols, or other utilization management tools that delay or complicate access to care. These challenges are particularly acute for patients with complex medical histories. Some patients are not good candidates for hormone therapy and require alternative treatments, yet those nonhormonal options may come with high out-of-pocket costs or limited coverage. As a result, the patients who often need individualized care the most can face the greatest barriers to obtaining it. Part of my time is spent providing care to women that are under or uninsured. I try to be creative in finding affordable, evidence-based options-whether that means choosing a generic medication or tailoring treatment to what a patient can realistically afford. When women cannot afford care, they may delay treatment or turn to providers offering treatments that are unproven, expensive, or potentially harmful. We need to make sure women have access to affordable, evidence-based care before they reach that point. Question: Many women report that their menopause symptoms are dismissed, misdiagnosed, or not adequately addressed in clinical settings. What barriers do clinicians face in recognizing and treating menopause-related symptoms? Response: I completely understand why patients can feel like they are not being heard. It is important that patients get timely access to the care they need. When women in their 40s come into my exam room with new symptoms, my first responsibility is to make sure we are not missing something very serious. Perimenopause symptoms can mimic symptoms of other potentially life-altering conditions/diseases, so sometimes that means testing and ruling out those conditions before we can confidently say, "This is perimenopause." That process can take time, but we also need to make sure that once serious conditions have been ruled out, we recognize perimenopause as a likely explanation and help patients understand their options for managing their symptoms. Conversations about perimenopause and menopause can also take time, often longer than the time we have for an annual well-woman exam. I want to spend the necessary time with my patients, but I see hundreds of patients a week. Workforce shortages, inadequate physician reimbursement, and mounting administrative burdens limit the amount of time we can spend with each patient. Question: What steps should Congress consider to strengthen menopause education and training across medical schools, residency programs, and continuing medical education? Response: While there's plenty we do know about symptoms and how to manage them, historical and ongoing underinvestment in research in midlife women's health have caused frustrating gaps in our understanding of this natural transition. Investing in research - better evidence, better understanding of the female biology and lifespan-will bolster training and improve care. In addition to strengthening and expanding menopause research, Senator Murray's Advancing Menopause Care and Mid- Life Women's Health Act would also help expand health professional training. Residency programs are increasingly emphasizing menopause care, and additional federal investment would give programs the resources needed to expand educational opportunities and prepare clinicians to meet growing patient demand. Question: What role can federal student loan incentives play in recruiting medical graduates into high-demand subspecialties, particularly in underserved communities with gaps in access to care? Response: Federal student loan forgiveness and scholarship programs incentivize physicians to train and practice in physician workforce shortage areas. Residents come out of medical school with mounting student debt, which may impact in which specialty and where they choose to practice. These programs reduce the significant financial burden our future workforce faces. Question: The lack of widely available information and public education about managing menopause symptoms has allowed bad actors to target women online with misinformation. This includes promises of "miracle cures" that have not been evaluated for effectiveness or regulated by the FDA. How should women evaluate claims about products marketed for managing menopause symptoms, and where should patients look for evidence-based resources on the difference between FDA- approved therapies versus other remedies not regulated based on their safety and effectiveness? Response: Every day I have conversations with patients about the claims they hear, and the products marketed to them online. I welcome the conversation and am happy to answer their questions. My hope is that everyone can have access to a trusted clinician to have these discussions and make informed, individualized treatment decisions. Telehealth is a great resource and tool for this. But the reality is, not everyone has timely access to a clinician. I direct patients to trusted resources from organizations such as ACOG and the Menopause Society for evidence-based guidance. Especially at a time when health misinformation is increasingly prevalent, improved public health awareness and access to trusted, evidence-based information on menopause and mid-life women's health is urgently needed. Question: As research and access to therapies evolves, how can clinicians effectively communicate the benefits, risks, and remaining uncertainties in newly developed treatments? Response: As research and our understanding of menopause continue to evolve, clinicians have a responsibility to communicate what we know, what we do not yet know, and what the evidence tells us about both the benefits and risks of treatment. That starts with listening to the individual patient and understanding her symptoms, health history, concerns, and goals. There is not a one-size-fits-all approach to menopause care, and treatment decisions should be based on the best available evidence and an informed discussion between the patient and her physician. Question: I am pushing to pass the bipartisan Advancing Menopause Care and Mid-Life Women's Health Act, led by Senators Murray and Murkowski. The bill would make a historic investment of $275 million into critical biomedical, public health, clinical, and translational research through NIH. For far too long, mid- life women's health has suffered from underinvestment and systemic oversight; this bill provides dedicated resources to transform the standard of care. How would the workforce training provisions included in Senator Murray's bill help to make provider education more consistent? Response: Medical schools and residency programs are increasingly emphasizing menopause care within existing educational frameworks-- providing resources, like those included in the Advancing Menopause Care and Mid-Life Women's Health Act, will enable these programs to continue and even expand this work and encourage more programs to do the same. Question: We've heard from each of you about how additional research would drive advances in provider training, public education, and novel treatments. What do you view as the most pressing gap in menopause research? Response: More research is needed on additional effective treatments, and their long-term, later-in-life health benefits. Further research into the female biology across the lifespan is sorely needed. Bold investment will ensure health care professionals like me can connect patients who suffer from significant symptoms with affordable, evidence-based treatments, and improve my patients' long-term quality of life. U.S. Senate Special Committee on Aging "Half the Country, Zero Hearings: Meeting the Moment to end the Menopause Care Gap in America" September 16, 2026 Questions for the Record Jennifer Weiss-Wolf Ranking Member Kirsten E. Gillibrand Question: Despite limited federal investment in menopause and mid- life women's health research, we've made great advancements in treating symptoms of menopause, particularly with hormone therapy. However, many women still cannot access the care they need. From your perspective as an advocate and an author, what are the most significant barriers impacting women's ability to access treatment? How does that change based on where they live? Response: Access to treatment is impeded by the lack of trained clinicians, continued confusion around the safety and efficacy of FDA approved treatments, and often the cost of treatments and care. It is surely harder for women in rural areas and those in care deserts; but even for those who live in places with more options, wait times and cost can be a barrier. Question: What can Congress do to help address some of these barriers, like OB-GYN shortages, estrogen patch shortages, and insurance coverage disparities? Response: Congress can engage with the Food and Drug Administration to ensure meaningful oversight and demand more transparency on the part of manufacturers. Question: In your testimony, you share that a 2025 study found that only 26 percent of women have health insurance that covers FDA- approved menopause treatments and that one in five delayed it or passed it up due to financial concerns. Are there significant disparities in coverage policies for perimenopause and menopause treatments between commercial insurance plans and government programs like Medicare and Medicaid? Response: There is disparity even among private plans as well as government programs. Neither Medicaid nor Medicare require that menopause treatments be covered. One study shows that medical practices that claim to accept Medicaid patients often do not serve them well or at all. Question: If Congress were to change that, how do you think it would impact women's ability to access perimenopause and menopause care? How would that impact their lives? Response: Access to treatment that is life-changing - even life- saving - and should always be a top policy priority. Addressing affordability of that treatment vis-a-vis insurance coverage, including government programs, is one key way to do so. Question: In your testimony, you share several stories from women of the hundreds recounted to you as part of your advocacy work. From your perspective as an advocate for yourself and others, what core themes emerge in how menopause symptoms impact your health; your work; your family life; and your ability to access care? What do you think policymakers, health care providers, and the public need to better understand about the real-world impact of menopause? Response: Responding to (a) and (b) together: Menopause is not a singular or "one-size-fits-all" experience, and has different impacts on each person going through it. For some that might mean stress on the family unit; for others that might mean greater risk of immediate or long-term health issues; and still others it could translate to lost productivity and therefore lost wages. All stakeholders need to understand that menopause is hormonal and whole-body health - not just a temporary stage or something that has a quick fix. We have decades of systemic neglect and misinformation to undo. The sooner we start, the sooner we begin forging a healthier future. Question: Dr. Fenske's testimony emphasizes the impact of the national physician shortage of primary care providers and specialists on menopausal care, like OB-GYNs and geriatricians. With the cap on federally funded residency slots limiting our training capacity and mounting student debt deterring doctors from essential specialties, patients are struggling to find providers with specialized training. Patients shouldn't have to wait months for appointments, especially when they're in serious pain. How would your experience - and the experiences of the women you have interviewed - be different if you had more access to care and resources offered by clinicians? Response: See answers above. Question: Addressing drug shortages is a top priority for this committee, and I thank Chairman Scott for his leadership and partnership in working to secure our supply chain. Dr. Fenske's testimony highlights how the urgent need to address the shortage of frontline hormone therapies available to patients, particularly transdermal estrogen patches. How are these shortages impacting women's lives; women's work; women's families; and beyond? Response: The success women have on this medication is immediately undermined by their inability to obtain it and/or the extraordinary frustration and time wasted in having to chase it down, month after month. For some, the prescription cost increases due to copays covering only one moth versus a longer supply. Question: Sometimes FDA uses temporary regulatory flexibility to address a drug shortage. If the agency were to consider a supplemental patch supply while U.S. capacity catches up, what assurances would physicians and patients need regarding FDA review, manufacturing quality, inspections, labeling, and ongoing safety monitoring? Response: I cannot envision where a supplemental supply would come from; there is no compounded patch equivalent that I am aware of. Perhaps more education into alternative transdermal methods as well as oral estrogen would be a potential FDA campaign. Question: Factors like stigma and lack of public awareness continue to leave many women without reliable information or support during the menopause transition. What should a coordinated federal education and awareness effort include to ensure women, families, employers, and clinicians have accurate, evidence-based information about menopause and available care options? Response: Evidence-based information and resource guide in an easy to digest and disseminate medium; I think PSAs are a wonderful opportunity for Gen X and Millennials (who were raised on them!). Question: We've heard from each of you about how additional research would drive advances in provider training, public education, and novel treatments. What do you view as the most pressing gap in menopause research? Response: Fully knowing the preventive, pre-emptive, and/or proactive benefits of menopausal hormone therapy to chronic brain, bone, and heart health; and We need a new, modern version of the Study of Women's Health Across the Nation. (SWAN). SWAN is the longest longitudinal, multi-racial/ethnic study of women going through menopause, launched in 1994 and co-sponsored by NIH's Office of Research on Women's Health, the National Institute on Aging, the National Institute of Nursing Research, and the National Center for Complementary and Alternative Medicine. Preliminary ideas for expansion for a SWAN 2.0 would include: new cohorts, including Millennials and Gen X women; more equitable racial, ethnic and socioeconomic representation; inclusion of Veterans and women in military service; expanded geographical representation; and more comprehensive symptom tracking using modern technology. Senator Raphael Warnock Question: According to the Mayo Clinic, women experiencing menopausal symptoms are eight times more likely to report higher turnover, absenteeism, and work-related challenges compared to those not experiencing symptoms. Often between the ages of 45 and 55, many working women also balance taking care of their families as part of a sandwich generation while navigating menopause themselves. Ms. Weiss-Wolf, what is the economic impact of women leaving the workforce due to difficulty managing their menopause symptoms? Response: The Mayo Clinic puts numbers on that cost: an estimated $1.8 billion in lost work time per year and $26.6 billion annually when medical expenses are added, in the U.S. alone. Question: What unique challenges do women experiencing menopausal symptoms face, especially when they serve as sandwich caregivers for their family? Response: Gen X has been the poster child of the "sandwich generation" - raising children and caring for aging parent simultaneously. Factor in the physical impact of menopause and lack of access to care and treatment, and you have women shouldering an unmanageable and inequitable load. Question: How can Congress support women experiencing menopause who are in the workforce? What specific arrangements or flexibilities could improve working conditions for those who also serve as sandwich caregivers? Response: I really don't think that accommodations are the answer. Those I most often see touted miss the mark: some, like desk fans and cooling rooms, are mere surface level fixes and have short-term value at best, insufficient to meet the decade-plus of need that goes well beyond hot flashes; others, like flex- time and expanded benefits, are important but not likely available to women in low-wage or hourly or service jobs. And there is no employee in this country guaranteed meaningful federal protection under the law from discrimination on the basis of menopause. Really, we need to make investments in research, education, and affordable and accessible treatments. Thos are the reforms that will go the longest way in supporting women. U.S. Senate Special Committee on Aging "Half the Country, Zero Hearings: Meeting the Moment to end the Menopause Care Gap in America" September 16, 2026 Questions for the Record Dr. Suzanne Silverman Fenske Ranking Member Kirsten E. Gillibrand Question: In your testimony, you share how your own OB-GYN education was focused largely on reproductive issues and pregnancy. You state that you received very little menopause training in your core curriculum. Now working with women of all ages, how did you develop your expertise in the areas of practice where you feel your core curriculum training fell short? Response: I completed training with The Menopause Society and became a Menopause Society Certified Practitioner. Question: In your practices, to what extent does a patient's coverage policy dictate their ability to access the treatments they need? Response: I have found that coverage for generic estradiol patch, generic estradiol daily gel packet and progesterone have been good. Coverage for the products that do not have generics (such as evamist, femring, estring, intrarosa) has been poor. With the limited availability of patches and gel, this has limited access to HRT for many women. Question: One in ten0 women leave the workforce because of menopause symptoms. They're leaving at the peak of their careers and taking their experience with them. What are some of the more common symptoms of menopause, and how does that impact women at work? Response: There are at least 34 symptoms of perimenopause/menopause. Hot flashes/night sweats affect about 75% of women and can significantly impact sleep and affect daytime work and comfort as well. Sleep disturbances/insomnia are a symptom in and of itself with difficulty falling asleep, and/or waking between 2 am and 4 am or early morning waking. Poor sleep has a direct impact on work performance. The psychological symptoms of anxiety, depression, mood swings impact ability to perform work. The cognitive symptoms of brain fog and difficulty with memory and concentration make work performance suboptimal and difficult. Question: What are the most effective workplace supports that employers can adopt for their affected workers? What advice would you give to managers and human resource professionals? Response: Connection to appropriate care. This would mean having medical insurance that adequately covers menopause care and, possibly, having a referring relationship with perimenopause/ menopause telehealth companies that could treat if the woman does not currently have a knowledgeable practitioner. Question: Your testimony emphasizes the impact of the national physician shortage of primary care providers and specialists on menopausal care, like OB-GYNs and geriatricians. With the cap on federally funded residency slots limiting our training capacity and mounting student debt deterring doctors from essential specialties, patients are struggling to find providers with specialized training. Patients shouldn't have to wait months for appointments, especially when they're in serious pain. How would expanding the number of Graduate Medical Education slots expand patient access to providers equipped to treat their symptoms? Response: Yes, more slots would allow for more trained practitioners, but this is not the sole solution to this issue. As mentioned, there is not enough incentive for medical students to go into these fields since compensation is low and their student debt is high. This has to be readdressed at insurance reimbursement level for these appointments. The average commercial reimbursement to a physician for seeing a 30+ minutes menopause visit is $128. In order to have more physicians in primary care and in menopause care, the insurance reimbursement must reflect the amount of time and care that physicians put into these patients. Salaries for primary care should be higher. Surgical specialties earn approximately 90% more than primary care physicians. The average debt from medical school is close to a quarter of a million dollars. Something has to change to encourage medical students to go into primary care. This could mean lower medical school costs or high primary care salaries (better reimbursement from insurance companies) or the government could provide some sort of stipend or loan grievance to offset. Question: Addressing drug shortages is a top priority for this committee, and I thank Chairman Scott for his leadership and partnership in working to secure our supply chain. Your testimony highlights how the urgent need to address the shortage of frontline hormone therapies available to patients, particularly transdermal estrogen patches. What happens to patient care when treatments suddenly become unavailable due to a supply shortage? Response: Thank you for your attention to this urgent matter. Many patients have had to discontinue their HRT due to shortage. The options that come in generics (such as the patch and the daily gel) have been in short supply and many insurance companies will not cover alternatives since they are brand. The recommendations have been to switch to oral estradiol tablets. This issue with this substitution is that oral estrogen confers a small but real increased risk of stroke and blood clot. The transdermal options do not confer that same risk. Having women switch from their transdermal preparations to oral because of the shortage would lead to increased cases of stroke and blood clot. Many women do not feel comfortable with this increased risk. Currently, women are put in the difficult position of either discontinuing their HRT which has alleviated their symptoms or paying out of pocket or switching to oral preparation that have additional risks. Question: How can the federal government use its oversight capabilities to facilitate a sufficient supply of estrogen patches for American patients? Response: The Federal Government is in a unique position to facilitate sufficient supply by assisting in removing regulatory obstacles, recruit additional manufacturers if needed, incentivize domestic manufacturing, meet with manufacturers to identify the rate-limiting steps in production, expedite manufacturing approvals. In addition, the government can require border coverage for FDA-approved menopause hormone therapy and limit prior authorizations (depending on the insurance company). Question: Sometimes FDA uses temporary regulatory flexibility to address a drug shortage. If the agency were to consider a supplemental patch supply while U.S. capacity catches up, what assurances would physicians and patients need regarding FDA review, manufacturing quality, inspections, labeling, and ongoing safety monitoring? Response: Sourcing from a country that meets or exceeds FDA's current standards and assurances that the supply will be adequate until US capacity catches up. Question: Factors like stigma and lack of public awareness continue to leave many women without reliable information or support during the menopause transition. As a Women's Health Ambassador for the HHS Office on Women's Health, how does the quality of available information about hormones, lifestyle, and overall health impact outcomes for patients? Response: Unfortunately there is a reliance on social media influencers, artificial intelligence and unqualified providers. This has led to misinformation, delay in treatment, fear and use of "snake oil" solutions. Question: The lack of widely available information and public education about managing menopause symptoms has allowed bad actors to target women online with misinformation. This includes promises of "miracle cures" that have not been evaluated for effectiveness or regulated by the FDA. How should women evaluate claims about products marketed for managing menopause symptoms, and where should patients look for evidence-based resources on the difference between FDA-approved therapies versus other remedies not regulated based on their safety and effectiveness? Response: The government should create an information page on menopause that reviews the data for FDA approved therapies as well as supplements and lifestyle intervention stating what data exists and when data is lacking. Question: As research and access to therapies evolves, how can clinicians effectively communicate the benefits, risks, and remaining uncertainties in newly developed treatments? Response: For primary care physicians and OBGYNs, there needs to be a conversation with women at their annual examinations, perhaps at the age of 40. We are instructed to discuss nutrition, exercise, need for mammograms, contraception as part of our annuals, but there should be an expectation of a perimenopause/ menopause conversation at age 40. While for some women this will be after their symptoms have started, on average, this would cover most women ahead of the symptoms. Question: We've heard how additional research would drive advances in provider training, public education, and novel treatments. What do you view as the most pressing gap in menopause research? Response: Lack of a large, adequately powered randomized trial of transdermal estradiol plus oral progesterone assessing long- term breast cancer incidence and mortality, myocardial infarction, stroke and blood clot, all cause mortality and cardiovascular mortality. ======================================================================= Statements for the Record ======================================================================= [GRAPHICS NOT AVAILABLE IN TIFF FORMAT] [all]